Genetics Bundle

This publication has been discontinued on May 12, 2011.

Below is the updated product.

Introduction

Abstract

The Genetics Bundle includes the following reports:

• Bioinformatics Markets.
• DNA Sequencing and PCR Markets.
• Gene Expression Reagents Markets.
• Genomics World Markets.
• Microarray Markets.
• Personalized Medicine.
• Pharmacogenomics for Clinical Use and in Drug Development.
• RNA Interference Markets.

Bioinformatics Markets

The life science informatics marketplace--known as bioinformatics--is set to expand as high-tech companies infiltrate this arena and biopharmaceutical companies incorporate key informatic solutions into their business strategies. TriMark Publications believes that many of the segments of bioinformatics described in this report offer an unusual opportunity for accelerated expansion within the coming years. This study is arranged to provide an overview of bioinformatics market segments and offer evidence that these segments are poised for significant future growth. Each segment is accompanied by analysis and forecasts by product type and application. This analysis surveys the bioinformatics market and the latest information regarding emerging new products and industry trends. The study will quantify and qualify the bioinformatics market segments as an area of research, product development and investment. Forecasts of the bioinformatics market and an analysis of products in the worldwide information-processing market will provide a basis for understanding the significance of past developments and future possibilities within this market category.

DNA Sequencing and PCR Markets

The focus of this TriMark Publications report is to describe the specific segment of the life sciences market called DNA sequencing. This analysis includes all of the generally-accepted DNA-oriented analytical activities that are currently used today, such as enabling technologies like polymerase chain reaction (PCR). It examines these measurement technology platforms and their reagents and supplies as utilized in biotechnology research, pharmacology and healthcare. Generally, diagnostic tests which are marketed primarily as over-the-counter products directly to patients are not included in this study, although there is inevitably some overlap. This examination will: 1) identify viable technology drivers through a comprehensive look at various platform technologies for molecular sequencing, including immunoassays electrophoretic methods, probe-based nucleic acid assays, microarrays and non-PCR sequencing; 2) obtain a complete understanding of the chief molecular sequencing tests for predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic applications; 3) discover feasible market opportunities via an identification of high-growth applications in different therapeutic areas, with a focus on the biggest and expanding markets-communicable diseases, cardiology and oncology; and 4) focus on global industry development through an in-depth analysis of the major world markets for molecular sequencing, including forecasts for growth.

Gene Expression Reagents Markets

The area of gene expression reagents is one of the newest and most important sectors of pharmaceutical and bioscience research and development. The term gene expression reagents refers to chemicals that are used in gene expression experiments that are performed to determine whether a particular gene is expressed-i.e., present-and in some cases at what levels, in a biological sample. The purpose of this TriMark Publications report is to describe the specific segments of the global gene expression reagents market. Within this area, the study covers those segments that are highly active in terms of innovation and growth. Specifically, this review examines the markets for gene expression reagents and small lab equipment all the way up to highly automated platforms. Emphasis is on those companies that are actively developing and marketing gene expression reagents for genomics research in the academic sector and the pharmaceutical, bioscience industry. This study concentrates on the laboratory reagent market segment and the companion gene expression reagents sector in the U.S. and around the world that use materials for genetic research. Particular attention is paid to those areas of the gene expression reagents sector that are showing the greatest growth or the most innovation.

Genomics World Markets

Genomics is transforming the pharmaceutical industry. Companies are moving from drug discovery and development based on medicinal chemistry to the design of drugs based on information provided by genomics. Virtually all of the major pharmaceutical houses have either formed partnerships with genomics firms that began to emerge in the early 1990s or have created in house genomics divisions. The aim of this TriMark Publications study is to provide in depth information on the developing market for genomics products and services. The report will include detailed market analyses and discussions of industry trends in order to assess the impact of genomics on the current and emerging pharmaceutical and diagnostic markets. Forecasts and trends were developed from interviews with industry sources, as well as from an assessment of available and emerging technologies. The report focuses on how researchers are applying new genomic approaches to drug discovery and development, and on how these technologies can be used most effectively and in a high throughput capacity. Case studies analyzing particular applications of genomic technologies to specific disease related research are provided, and future trends and developments are forecasted. Information to prepare this study was derived from interviews with product managers, marketing strategists, research executives and others. These individuals are employed at leading genomics firms or in pharmaceutical and biotechnology companies that either contract with these firms or have developed in house genomics capabilities.

Microarray Markets

A microarray is an arrangement of miniaturized test sites or "spots" on a surface. Each spot is usually no more than 250 micrometers in diameter and contains biological molecules-usually DNA or protein-which act as probes for a test sample applied to the array. The surface may be a glass slide, a plastic plate with wells or a polymer bead. The microarray format allows many tests or experiments to be performed simultaneously, in parallel, leading to the generation of huge amounts of biological information for the application of only a tiny amount of sample. Microarrays are often also known as "biochips". The purpose of this TriMark Publications report is to describe the specific segment of the microarray market aimed at analysis of proteins and DNA. Protein microarray applications include: 1) expression profiling; 2) serum-based diagnostics; 3) protein-protein binding assays; 4 drug-target binding; and 5) receptor epitope binding. It examines the market for DNA and protein array testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including the research labs, hospital labs, and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the protein array market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company' s market position.

Personalized Medicine

Personalized medicine and pharmacogenomics are inextricably linked. Pharmacogenomics is the use of genetic variations (such as SNPs, gene expression variability, or other molecular signatures) to understand and correlate with differential response to pharmaceutical agents (drugs). Pharmacogenomics can be deployed clinically to stratify patients into responders and non-responders and this practice is termed personalized medicine. The purpose of this TriMark Publications report is to describe the specific market segment of the diagnostics market called personalized medicine. To frame the context of current approaches, pharmacogenomics seeks to identify and validate the signature(s) of molecular analytes and these are converted to assays using the tools of molecular diagnostics. The deployment of these molecular diagnostics assays on defining and targeting patient populations is the domain of personalized medicine. This study includes all of the generally-accepted imaging activities that are currently used in personalized medicine, including pharmacogenomics, genomics and theranostics. It examines associated clinical market segments in which personalized medicine has taken a prominent role including cancer treatment, cardiology and neurology markets.

Pharmacogenomics for Clinical Use and in Drug Development

Pharmacogenomics, the science of individualizing drug therapy based on the genetic makeup of individual patients, offers an unusual opportunity for future market growth. Applying pharmacogenomics would allow doctors to treat specific segments of the population based on their particular responses to a drug. The knowledge of the likely effectiveness of a drug in a patient makes the drug more reliable, and fewer drugs would have to be taken off the market due to adverse reactions in some, but not all, of the patients to whom they were administered. Additionally, reducing the occurrence of adverse effects to a drug effectually reduces the cost of patient care overall. This TriMark Publications study examines the market for diagnostic tests based on this science and the clinical measurement methods, the reagents and supplies being utilized in clinical medicine and the pharmaceutical industry. This report presents an overview of the latest information regarding emerging new products and industry trends and will not only quantify, but also, qualify the pharmacogenomic market segments as an area of research, product development and investment opportunity. Forecasts of the pharmacogenomic market and an analysis of products in the worldwide diagnostics market will provide a basis for understanding the significance of past developments and the immense possibilities of the future.

RNA Interference Markets

Since its discovery, the naturally occurring RNA (ribonucleic acid) interference effect has been acclaimed as the most exciting technical breakthrough in biological research in the last decade. Some industry analysts predict that RNA interference (RNAi) may even surpass PCR as a top technology. RNAi allows scientists to silence the expression or effect of a gene under study. This is known as gene knockdown. This field has rapidly emerged as a fast-growing new market. The purpose of this TriMark Publications report is to review the market for RNAi testing equipment and supplies. RNAi is a mechanism in molecular biology where the presence of certain fragments of double-stranded RNA (dsRNA) interferes with the expression of a particular gene which shares a similar sequence with the dsRNA. This study defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence market size and growth for RNAi testing. The main objectives of this study are to: 1) understand the different sectors of RNAi testing market and to look at a description of the instruments, reagents and supplies marketed by major companies in each segment; 2) obtain a complete understanding of the individual RNAi-testing platforms-from basic principles to clinical applications; 3) discover feasible market opportunities by identifying high-growth applications in different analytical diagnostic areas, with a focus on the biggest and expanding markets; 4) focus on global industry developments and trends through an in-depth analysis of the major world markets for RNAi measurement technology, including growth forecasts; and 5) present market figures related to the current value of RNAi testing, market projections, market share, key players and sector growth rates.

Table of Contents

Bioinformatics Markets

1. Overview

• 1.1 Statement of Report
• 1.2 About this Report
• 1.3 Scope of this Report
• 1.4 Methodology
• 1.5 Executive Summary

2. Introduction

• 2.1 Global Bioinformatics Products Industry
• 2.2 Computers and Biology
• 2.3 Bioinformatics and the Internet
• 2.4 Company Evaluation Overview
• 2.5 Market Outlook
• 2.6 Competitive Structure
• 2.7 Applications of Bioinformatics
  • 2.7.1 Medicine
  • 2.7.2 Microbial Genomics
  • 2.7.3 Agriculture
• 2.8 R&D
  • 2.8.1 Allocation of R&D
  • 2.8.2 Traditional Drug Discovery Process
  • 2.8.3 Drug Discovery and Bioinformatics
  • 2.8.4 Collaborative Agreements
• 2.9 The Human Genome Project (HGP)
  • 2.9.1 Goals of the Human Genome Project
  • 2.9.2 Benefits of the Human Genome Project
• 2.10 Barriers to Entry
• 2.11 Proteomics and Databases
  • 2.11.1 Protein Database Standards
  • 2.11.2 Future Trends

3. The U.S. Bioinformatics Market

• 3.1 Overview
• 3.2 Market Restraints and Drivers
  • 3.2.1 Market Restraints
  • 3.2.2 Market Drivers

4. Genomics

• 4.1 The Biotechnology Industry
• 4.2 The Development of a Genomics Market
  • 4.2.1 Market Drivers
  • 4.2.2 Market Restraints
  • 4.2.3 Market Size and Growth Projections
  • 4.2.4 The U.S. Genomics Market
• 4.3 Biochips and DNA Microarrays
  • 4.3.1 Key Challenges
  • 4.3.2 Freeware
  • 4.3.3 New Tools
• 4.4 Bioinformatics
• 4.5 Disease Targets
• 4.6 Functional Genomics
• 4.7 Gene Sequencing
• 4.8 Gene Sequence Variation Detection
• 4.9 Comparative Genomics
• 4.10 Genome Database Arrays
• 4.11 High-throughput Genomics
  • 4.11.1 High-throughput Technology
  • 4.11.2 Lab on a Chip
• 4.12 Pharmacogenomics
• 4.13 Probe Arrays
  • 4.13.1 Gene Expression Monitoring Arrays
  • 4.13.2 DNA Analysis Arrays
• 4.14 Proteomics
• 4.15 Sequencing
• 4.16 Single Nucleotide Polymorphisms (SNPs)
• 4.17 Structural Genomics
• 4.18 Photolithography
• 4.19 Instrumentation

5. The Bioinformatics Industry

• 5.1 Definition and Role of Bioinformatics
  • 5.1.1 Bioinformatics Sector Overview
  • 5.1.2 The Future Status of Bioinformatics
  • 5.1.3 Barriers to Growth
• 5.2 Types of Data and Bioinformatics Applications
  • 5.2.1 Validated Core Modeling Technology
  • 5.2.2 Broad Applicability
  • 5.2.3 Data Management Compliant with Industry Standards
  • 5.2.4 Open Architecture
  • 5.2.5 Ease of Use
  • 5.2.6 Increased Access
• 5.3 Functions of Bioinformatics Software
  • 5.3.1 Data Management
  • 5.3.2 Data Transformation
  • 5.3.3 Data Collaboration
  • 5.3.4 Interface for Online Data Sources
• 5.4 Target Markets for Informatics Software
• 5.5 Steps Involved in Bringing a Drug to Market
• 5.6 Costs Incurred in Developing a New Drug
• 5.7 Industry Drivers and Challenges
• 5.8 Industry Risks
• 5.9 Products of Bioinformatics
• 5.10 Bioinformatics Processes
• 5.11 Informatics Tools and Functionalities
  • 5.11.1 Sequence to Structure
  • 5.11.2 Lead Identification and Optimization
  • 5.11.3 Development and Formulation
  • 5.11.4 Improving Materials and Processes
  • 5.11.5 Other Materials-Based Industries
• 5.12 Role of Bioinformatics in the Biotechnology Value Chain
• 5.13 Bioinformatics Market Segment
  • 5.13.1 Databases
  • 5.13.2 Hardware
  • 5.13.3 Software
  • 5.13.4 Bioinformatics Services
• 5.14 Bioinformatics Market Size
  • 5.14.1 Sales and R&D
  • 5.14.2 IT Budget
  • 5.14.3 Projected Bioinformatics Market Size
• 5.15 Global Market Perspective

6. Bioinformatics Business

• 6.1 Bioinformatics Business Models
  • 6.1.1 Changing Business Models
  • 6.1.2 Competition for Pure Play Informatics Companies
  • 6.1.3 Non-Profit Organizations
  • 6.1.4 In-House Bioinformatics Solutions
  • 6.1.5 Large IT Companies
• 6.2 Bioinformatics Target Disciplines
  • 6.2.1 Comparative Genomics
  • 6.2.2 Pharmacogenomics
  • 6.2.3 Functional Genomics
  • 6.2.4 Proteomics
  • 6.2.5 Structural Genomics
  • 6.2.6 Image Informatics
  • 6.2.7 Clinical Trial Informatics
  • 6.2.8 Cheminformatics
• 6.3 Bioinformatics Architecture
• 6.4 Bioinformatics Applications
  • 6.4.1 Data Search Tools
  • 6.4.2 Data Visualization Tools
  • 6.4.3 Data Mining and Clustering
  • 6.4.4 Enterprise Solutions
  • 6.4.5 Data Warehousing
• 6.5 Evaluation of Bioinformatics Solutions
  • 6.5.1 Requirements of Study
  • 6.5.2 Shortlisting the Options
  • 6.5.3 Scoring Patterns
  • 6.5.4 Performance
  • 6.5.5 Data Storage
  • 6.5.6 Data Management in Drug Discovery
  • 6.5.7 Key Issues in Bioinformatics Data Storage
• 6.6 Convergence of Industries
• 6.7 Proteins as a Driver
• 6.8 Current Bioinformatics Research
• 6.9 New Bioinformatics Modeling Algorithms
• 6.10 3D Modeling
• 6.11 Patenting Bioinformatics Algorithms

7. Recent Industry Activity

• 7.1 Collaborations and Acquisitions
• 7.2 Product Development and Launches

8. Corporate Profiles

• 8.1 Abbott Laboratories
• 8.2 Abgenix
• 8.3 Ablynx
• 8.4 Accelrys
• 8.5 Affimed Therapeutics
• 8.6 Affitech
• 8.7 Affymetrix
• 8.8 Agencourt Bioscience Corporation
• 8.9 Agensys
• 8.10 Agilent Technologies
• 8.11 Alexion Pharmaceuticals
• 8.12 AlgoNomics
• 8.13 ALLEZ Software
• 8.14 Amgen
• 8.15 Antisoma
• 8.16 Applied Biosystems
• 8.17 Arana Therapeutics
• 8.18 Ariadne Genomics
• 8.19 Array Genetics
• 8.20 Astellas Pharma
• 8.21 AstraZeneca
• 8.22 Automated Handling Systems
• 8.23 Avesthagen, Limited
• 8.24 Bioalma
• 8.25 BIOBASE Biological Databases
• 8.26 BioCarta
• 8.27 Biodatabases (AMITA Corporation)
• 8.28 BioDiscovery
• 8.29 Biogen Idec
• 8.30 BioInformatics
• 8.31 BioInformatics Services
• 8.32 BioInformatics Solutions
• 8.33 Biomax Informatics
• 8.34 BioServe Technologies
• 8.35 Biosiris
• 8.36 BioSoftSolutions
• 8.37 Biotique Systems
• 8.38 BioInvent International
• 8.39 Biosite Discovery
• 8.40 BioWa
• 8.41 BioWisdom
• 8.42 Bio-Xtal
• 8.43 Boehringer Ingelheim
• 8.44 Cambridge Antibody Technology Group
• 8.45 Capital Genomix
• 8.46 Celera Group
• 8.47 Cellectis
• 8.48 Cellomics
• 8.49 CeuticalSoft
• 8.50 Chemical Computing Group
• 8.51 Cimarron Software
• 8.52 CLONDIAG Chip Technologies
• 8.53 CodonCode Corporation
• 8.54 CompuDrug International
• 8.55 Compugen USA
• 8.56 Corimbia
• 8.57 Crucell
• 8.58 CSIRO Bioinformatics
• 8.59 CuraGen Corporation
• 8.60 CyberGene
• 8.61 Cytogen
• 8.62 Data Unlimited International
• 8.63 deCODE Genetics
• 8.64 Decodon
• 8.65 Deltagen
• 8.66 Digilab
• 8.67 DNA Software
• 8.68 DNAPrint Genomics
• 8.69 DNA Star
• 8.70 DxS
• 8.71 Dyax Corp.
• 8.72 Eisai
• 8.73 Elan Corporation
• 8.74 Electric Genetics Corporation
• 8.75 Elusys Therapeutics
• 8.76 Entagen
• 8.77 Entelos
• 8.78 Enzon Pharmaceuticals
• 8.79 Epigenomics
• 8.80 ePitope Informatics
• 8.81 EraGen Biosciences
• 8.82 European Bioinformatics Institute (EBI) Industry Programme
• 8.83 Evolutionary BioInformatics
• 8.84 Genamics
• 8.85 GeneData
• 8.86 Gene Logic
• 8.87 Genentech
• 8.88 Geneva Bioinformatics (GeneBio)
• 8.89 Genmab
• 8.90 GenOdyssee
• 8.91 Genolyze
• 8.92 Genomatica
• 8.93 GenomeQuest
• 8.94 Genomic Solutions
• 8.95 Genomining
• 8.96 Genovac
• 8.97 Genzyme
• 8.98 Geospiza
• 8.99 GlaxoSmithKline
• 8.100 Glycominds
• 8.101 Health Discovery Corporation
• 8.102 Hitachi Corporate Technology Group
• 8.103 IBM Life Sciences
• 8.104 ImClone Systems
• 8.105 ImmunoGen
• 8.106 Immunomedics
• 8.107 Improved Outcomes Software
• 8.108 INCOGEN
• 8.109 Incyte Corporation
• 8.110 Informagen
• 8.111 Ingenuity Systems
• 8.112 InNexus Biotechnology
• 8.113 Insilicos
• 8.114 Intrexon Corporation
• 8.115 Invitrogen Corporation
• 8.116 IO Informatics
• 8.117 Johnson & Johnson
• 8.118 LabVantage Solutions
• 8.119 Lexigen
• 8.120 Lifespan Biosciences
• 8.121 Lion Bioscience
• 8.122 MathEcology
• 8.123 Matrix Science
• 8.124 Medarex
• 8.125 Medicel
• 8.126 MedImmune
• 8.127 Merus
• 8.128 METabolic Explorer
• 8.129 Metahelix Life Sciences
• 8.130 Metalife
• 8.131 Micromet
• 8.132 Millennium Pharmaceuticals
• 8.133 Molecular Connections
• 8.134 Molecular Networks
• 8.135 Molecularware
• 8.136 MorphoSys
• 8.137 Nexus Genomics
• 8.138 Nonlinear Dynamics
• 8.139 Novartis
• 8.140 Ocimum Biosolutions
• 8.141 OmniViz
• 8.142 Partek
• 8.143 PDL BioPharma
• 8.144 Perlegen Sciences
• 8.145 Philogen
• 8.146 Philotec
• 8.147 Prokaria
• 8.148 Quantiom Bioinformatics
• 8.149 Relevant Software
• 8.150 Roche
• 8.151 Rosetta Inpharmatics
• 8.152 Sanofi-Aventis
• 8.153 SBI Science
• 8.154 Seascape Learning
• 8.155 Seattle Genetics
• 8.156 Scil Proteins
• 8.157 Simulations Plus
• 8.158 Spotfire
• 8.159 Strand Life Sciences
• 8.160 Sun Microsystems
• 8.161 Symphogen
• 8.162 Syngene
• 8.163 Tahoe Informatics
• 8.164 Tanox
• 8.165 3rd Millennium
• 8.166 ThromboGenics
• 8.167 Thomson Reuters
• 8.168 TIB MOLBIOL
• 8.169 Trion Pharma
• 8.170 Tripos
• 8.171 UBI Life Sciences
• 8.172 Viventia Biotech
• 8.173 VizX Labs
• 8.174 Wyeth
• 8.175 Xcellerex
• 8.176 Xencor
• 8.177 Xoma
• 8.178 Xpogen

INDEX OF FIGURES

• Figure 4.1: Representation of Biotechnology Market, Geographically, 2008
• Figure 5.1: Informatics Applications along the Drug-Discovery Value Chain
• Figure 5.2: Functions of Bioinformatics Software in Research
• Figure 5.3: EMBL Database Growth, 1995-2008
• Figure 5.4: The Steps Involved in Bringing a Drug to Market
• Figure 5.5: The Breakdown of Total Costs in New Drug Development, 2007
• Figure 5.6: The Role of Bioinformatics in the Biotechnology Value Chain
• Figure 5.7: Worldwide Pharmaceutical Sales and R&D Expenditures, 2000-2013
• Figure 5.8: Worldwide Growth in IT Budget, 2000-2013
• Figure 5.9: Worldwide Bioinformatics Market, 2000-2013
• Figure 6.1: Steps of a Proteomics Experiment
• Figure 6.2: Bioinformatics Architecture

INDEX OF TABLES

• Table 2.1: Leading Biotechnology Companies
• Table 2.2: Total of Domestic U.S. R&D, 2006-2013
• Table 2.3: Global Biotechnology Market, 2007
• Table 2.4: SIB Informatics Databases
• Table 4.1: The U.S. Biotechnology Industry Size and Revenue, 2000-2007
• Table 4.2: Global Biotechnology Industry Major Segments
• Table 4.3: Genomics Sector Market Size, 2006-2013
• Table 4.4: Total Biochip Market, 2007-2013
• Table 4.5: Selected Competitors in the Biochip Market
• Table 4.6: Biochip Microarray Products
• Table 4.7: Bioinformatics Tools
• Table 4.8: Functional Genomics Companies Building Advanced Integrated Platforms and Substantial Databases
• Table 4.9: Companies Using New Genomic Tools
• Table 4.10: Non-DNA-Based Chip Suppliers
• Table 4.11: Robotics or "Lab-on-a-Chip" Market Sector
• Table 4.12: Key High-throughput and Systemic Approaches in Genomic Analysis
• Table 4.13: Pharmacogenomics Segment Players
• Table 4.14: The Worldwide Market for Pharmacogenomics, 2006-2013
• Table 4.15: Competitors in the SNP Genotyping Segment
• Table 4.16: Scanning and Detection Technology Suppliers
• Table 5.1: Data Sources and Bioinformatic Investigations
• Table 5.2: Drivers and Challenges of the Bioinformatics Industry
• Table 5.3: Bioinformatics Activities, Sub-Activities and Key Players
• Table 5.4: Bioinformatics Market Size, 2006-2013
• Table 5.5: Cheminformatics Market Size, 2006-2013
• Table 5.6: In-silico Informatics Market Size, 2006-2013
• Table 5.7: Bioinformatics Hardware and Systems Market Size, 2006-2013
• Table 6.1: Alliances between IT/Telecom and Biotechnology Firms
• Table 6.2: Types of Intellectual Property Protection for Bioinformatics Tools

DNA Sequencing and PCR Markets.

1. Overview

• 1.1 Statement of Report
• 1.2 About This Report
• 1.3 Scope of the Report
• 1.4 Methodology
• 1.5 Executive Summary

2. Introduction to DNA Sequencing and Amplification and PCR Technology

• 2.1 Science Overview: Introduction to DNA
  • 2.1.1 DNA Sequencing and PCR Applications Space
  • 2.1.2 Proteomics
  • 2.1.3 Products for the Genomics Market
• 2.2 The Impact of the Human Genome Project on Molecular Biology
• 2.3 Impact of DNA Sequencing Techniques on Biotechnology, Pharmaceutical and Healthcare Industries
• 2.4 Molecular Diagnostics in the Post-genomic Era-The Role of SNPs
• 2.5 Advances in Molecular Diagnostic Technologies
• 2.6 The Use of PCR Technology
• 2.7 Genetic Variability and Disease

3. Market Analysis of PCR and DNA Sequencing Product Market

• 3.1 Overview of the Sequencing and Amplification Market
  • 3.1.1 Highlights of DNA Sequencing Market
  • 3.1.2 Genomic Analysis Market Development
  • 3.1.3 Leading U.S. and Canadian Companies Offering Sequencing Technology Platforms
  • 3.1.4 Competition
  • 3.1.5 Markets for DNA Sequencing
  • 3.1.6 Market Opportunity
  • 3.1.7 Market Dynamics
  • 3.1.8 Overview of Current DNA Sequencing Technology Platforms and Players
  • 3.1.9 Limitations of Current Sequencing Technologies
  • 3.1.10 Overview of the Life Science Marketplace
  • 3.1.11 Research Laboratories
    • 3.1.11.1 Market Share
• 3.2 Paradigm Shift in Drug Discovery and Development
  • 3.2.1 Systems Biology and the Need for More Effective Tools
  • 3.2.2 Molecular Medicine and the New Therapeutics
  • 3.2.3 Pharmacogenomics Using Genotyping and Phenotyping Clinical Biomarkers
  • 3.2.4 The Market
• 3.3 Detection of Amplified DNA
  • 3.3.1 Nucleic Acid Amplification Methods
  • 3.3.2 Amplification of Refractory Mutation System (ARMS)
• 3.4 DNA Reagent Applications Market Share and Key Players
  • 3.4.1 Product Description
    • 3.4.1.1 Pricing
• 3.5 PCR/DNA Testing Market Analysis
  • 3.5.1 Nucleic Acid-Amplification and Detection Systems: How Big a Market?
  • 3.5.2 Market Size 2004-2010 and Growth Projections in DNA Amplification Instrumentation
    • 3.5.2.1 U.S. Market
    • 3.5.2.2 European Market
  • 3.5.3 Market Share of Key Players in DNA Amplification
• 3.6 The Drivers of the Biotech Industry
  • 3.6.1 Isolation of DNA for PCR Profiling
  • 3.6.2 Analysis by PCR-Based DNA Typing
  • 3.6.3 Rapid Isolation of DNA for RFLP and PCR
  • 3.6.4 DNA for PCR-STR Typing
• 3.7 Biotechnology Instrumentation Outlook
  • 3.7.1 Products for the Genomics Market
  • 3.7.2 Genetic Analysis Products

4. Use of PCR and DNA Amplification Products

• 4.1 PCR Components
  • 4.1.1 Primers for PCR
  • 4.1.2 Equipment for PCR
• 4.2 Sources of DNA for PCR
• 4.3 PCR Primer Sequence
• 4.4 Thermostable DNA Polymerases
• 4.5 PCR Protocols
• 4.6 Microfluidic Automated DNA Analysis Using PCR

5. Technical Trends in PCR

• 5.1 Practical Applications of PCR
  • 5.1.1 Overview
• 5.2 Quality Control Issues in PCR
• 5.3 Determining Length of cDNA Product
  • 5.3.1 Direct Signal Amplification Using the Invader Assay
  • 5.3.2 Biosensor Technologies
    • 5.3.2.1 DNA Hybridization Biosensor Chips
    • 5.3.2.2 PNA-Based Biosensors
• 5.4 Novel Nucleic Acid Amplification Techniques
• 5.5 Microplate Readers
• 5.6 Genotyping Methods
  • 5.6.1 Use of DNA Sequencers
    • 5.6.1.1 Capillary-Based Sequencers
    • 5.6.1.2 Pyrosequencing
  • 5.6.2 Use of Microarrays
• 5.7 RiboMaker Detection System
• 5.8 RNA Isolation Kits
• 5.9 Nucleic Acid Sample Prep Platforms
• 5.10 DNA Microarrays
  • 5.10.1 The Technique
  • 5.10.2 The Market
  • 5.10.3 Gene Expression Monitoring Arrays
• 5.11 Emerging Markets of DNA Arrays
• 5.12 Alternatives to PCR Amplification
  • 5.12.1 Locked Nucleic Acids (LNAs)
  • 5.12.2 Multiplexed Nuclease-Protection Assay and ArrayPlate

6. Corporate Directory

• 6.1 Abbott Laboratories
• 6.2 Affymetrix
• 6.3 Agilent Technologies
• 6.4 AgriGen Biotech Pty
• 6.5 GE Healthcare
• 6.6 Applera Applied Biosystems
• 6.7 Avesthagen Gengraine Technologies, Pvt.
• 6.8 Bayer Corporation
• 6.9 BD Biosciences
• 6.10 Beckman Coulter
• 6.11 BGI Life Tech
• 6.12 bioMerieux
• 6.13 Bioneer
• 6.14 Bio-Rad Laboratories
• 6.15 BioTrove
• 6.16 Caliper LifeSciences
• 6.17 Cepheid
• 6.18 Cogenics (A subsidiary of Clinical Data)
• 6.19 CombiMatrix Corporation
• 6.20 Commonwealth Biotechnologies
• 6.21 Complete Genomics
• 6.22 CuraGen Corporation
• 6.23 Cytocell
• 6.24 Dako A/S
• 6.25 DiaDexus
• 6.26 DNA LandMarks
• 6.27 DNAVision
• 6.28 Enzo Biochem
• 6.29 Epicentre
• 6.30 Eppendorf AG
• 6.31 Eurofins Medigenomix
• 6.32 Exiqon
• 6.33 Febit Biomed
• 6.34 Geneart AG
• 6.35 GeneticTechnologies Limited
• 6.36 GeneWorks
• 6.37 Genisphere
• 6.38 Genizon BioSciences
• 6.39 Genovoxx
• 6.40 Gen-Probe
• 6.41 Genset
• 6.42 Genta
• 6.43 Genzyme
• 6.44 GVK BIO
• 6.45 Hamilton Thorne Biosciences
• 6.46 Helicos BioSciences Corporation
• 6.47 High Throughput Genomics
• 6.48 Hokkaido System Science
• 6.49 Hy Laboratories
• 6.50 Illumina
• 6.51 Incyte Corporation
• 6.52 Integrated DNA Technologies
• 6.53 Invitrogen
• 6.54 Inqaba Biotechnical Industries
• 6.55 Johnson & Johnson
• 6.56 Kreatech Holding BV
• 6.57 LI-COR
• 6.58 Sygnis Pharma AG
• 6.59 Lucigen
• 6.60 Luminex Corporation
• 6.61 Meridian Biosciences
• 6.62 Microchip Biotechnologies
• 6.63 Microsynth AG
• 6.64 MilleGen SA
• 6.65 Millennium Pharmaceuticals
• 6.66 MWG Biotech AG
• 6.67 Myriad Genetics
• 6.68 Nanogen
• 6.69 Nanosys
• 6.70 Nymox
• 6.71 Ocimum Biosolutions
• 6.72 Orchid Cellmark
• 6.73 Ostex
• 6.74 Pacific Biosciences
• 6.75 PamGene
• 6.76 Perlegen Sciences
• 6.77 PPD
• 6.78 PPGx
• 6.79 PrimmBiotech
• 6.80 Promega
• 6.81 Biotage
• 6.82 QIAGEN
• 6.83 Quidel
• 6.84 Research Biolabs Pte
• 6.85 Roche Diagnostics
• 6.86 Shanghai Sangon Biological Engineering Technology & Services Co.
• 6.87 Saturn Biotech
• 6.88 Sequenom
• 6.89 Sequetech
• 6.90 Shimadzu Biotech
• 6.91 Siemens AG
• 6.92 Tepnel Life Sciences
• 6.93 Third Wave Technologies
• 6.94 Visible Genetics
• 6.95 VisiGen Biotechnologies
• 6.96 Vysis
• 6.97 Wellcome Trust Sanger Institute
• 6.98 ZS Genetics

7. Market Trends and Forecasts

• 7.1 Market Dynamics
• 7.2 Future Considerations for Molecular Diagnostics
• 7.3 How Genomics is Transforming Pharmaceutical R&D
• 7.4 Cancer Markers
• 7.5 NAT and Personalized Medicine
• 7.6 Three Growth Areas of Molecular Diagnostics
• 7.7 RNA Detection
• 7.8 Ramification Amplification Method
• 7.9 Invader Assays/Third Wave Technologies
• 7.10 Molecular Beacons

8. Major Product Innovations/Launches in DNA Sequencing Industry

• 8.1 Major Product Innovations/Launches in DNA Sequencing Industry
• 8.2 Major Activities in DNA Sequencing Industry

LIST OF FIGURES

• Figure 2.1: Segment of Double-Stranded DNA Showing the Base-Pair Relationship
• Figure 3.1: Global Market for DNA Sequencing
• Figure 4.1: Cepheid' s I-CORE Module

LIST OF TABLES

• Table 3.1: Global Market for DNA Sequencing
• Table 3.2: DNA Sequencing Market Players
• Table 3.3: Major DNA Product Companies in Europe
• Table 3.4: Major DNA Product Companies in Asia and Australia
• Table 3.5: Major DNA Product Companies in Japan
• Table 3.6: Major DNA Product Companies in Rest of the World
• Table 3.7: Market Revenue and Market Share of DNA Sequencing Market Players
• Table 3.8: Thermal Cyclers Marketed by Applied Biosystems
• Table 3.9: Applied Biosystems' Real-Time PCR Systems
• Table 3.10: Applied Biosystems Genetic Analysis Instruments
• Table 3.11: Gene Expression Assays Offered by Applied Biosystems
• Table 3.12: SNP Genotyping Assays Offered by Applied Biosystems
• Table 3.13: Comparison of Established Genomic Analysis Technologies
• Table 3.14: Life Science Techniques Frequently Used
• Table 3.15: The Most Commonly Used Reagents Used by Life Science Researchers
• Table 3.16: The Most Commonly Used Instruments and Apparatus in Life Science Research
• Table 3.17: The Most Widely Reported Categories of Software in Life Science Research
• Table 3.18: Reagents and Equipment Sales for Use in DNA Sequencing Worldwide
• Table 3.19: Global Market for Tools and Consumables Used in Drug Discovery and Development, Clinical Diagnostics and Biomedical Research
• Table 3.20: Key Bioassay Technologies in the Life Sciences Industry
• Table 3.21: Nucleic Acid Amplification Methods
• Table 3.22: Properties of Various Acid Amplification Techniques
• Table 3.23: Amplification Reagent Product Description
• Table 3.24: Standard Prep Pricing
• Table 3.25: Small Target Prep Pricing
• Table 3.26: Hybridization Pricing
• Table 3.27: Analysis Pricing
• Table 3.28: U.S. Market Size 2004-2010 in DNA Amplification Instrumentation
• Table 3.29: Market Share of Key Players in DNA Amplification Thermostable Enzymes
• Table 3.30: Leading Manufacturers of Thermal Cyclers and Market Share
• Table 4.1: ThermoFisherMolecular Biology Thermal Cyclers
• Table 4.2: PCR Systems and Thermocyclers
• Table 5.1: RiboMaker"! Assays to be Introduced for Cancer and Pathogen Detection
• Table 8.1: The Key Bioassay Technologies in the Life Sciences Industry

Gene Expression Reagents Markets.

1. Overview

• 1.1 Objectives of the Report
• 1.2 Methodology
• 1.3 Scope of the Report
• 1.4 Executive Summary

2. Gene Expression

• 2.1 The Genomics Revolution
• 2.2 Basic Principles of Gene Expression
  • 2.3.1 Quantitative Real-Time PCR (qRT-PCR)
  • 2.3.2 PCR Labeling Chemistries
  • 2.3.3 TaqManR Probes
  • 2.3.4 SYBRR Green
• 2.4 Microarray Technology
• 2.5 Microarray Target Preparation and Hybridization
• 2.6 RNA Sample Preparation and Assessment

3. Gene Expression Reagents

• 3.1 Kit Format vs. Home-Brew Assays
• 3.2 Whole Product Solutions
• 3.3 Emerging Technologies

4. Market Environment

• 4.1 Institutional and Government Budgeting
• 4.2 Worldwide Investment in Genomics Technologies and Research
• 4.3 Industry Consolidation and Acquisitions

5. Market Drivers

• 5.1 Improved Assay Performance
• 5.2 Cost Effective Systems
• 5.3 Automation
• 5.4 Bioinformatics Solutions

6. Worldwide Market for Gene Expression Reagents

• 6.1 Life Science Research
• 6.2 Drug Discovery and Development, Molecular Diagnostics
• 6.3 Commercial Production
• 6.4 Gene Expression Market Size
  • 6.4.1 Real-Time PCR Revenue
  • 6.4.2 Commercial Microarray Revenue
  • 6.4.3 RNA Sample Preparation Revenue
• 6.5 Gene Expression Reagent Market by Region
• 6.6 Users of Gene Expression Products
  • 6.6.1 Core Laboratories
  • 6.6.2 Consortia
  • 6.6.3 Pharmaceutical and Biotechnology Companies
• 6.7 Affiliation
• 6.8 Job Function and Decision Makers

7. Key Applications

• 7.1 BioMarker Identification and Pharmacogenomics
• 7.2 Toxicogenomics
• 7.3 Molecular Diagnostics

8. Vendor and Product Selection

• 8.1 Product Adoption
• 8.2 Drivers for Product Switching

9. Leading Vendors

10. Marketing Strategies

• 10.1 e-Marketing and e-Commerce
• 10.2 Catalog
• 10.3 On-Site Cabinet Programs

11. Pricing Strategies

• 11.1 Price Elasticity
• 11.2 Strategies

12. Distribution Channels

13. Competitive Situation

14. Opportunities

15. Market Strategy Profiles, Leading and Selected Vendors

• 15.1 Applied Biosystems
  • 15.1.1 Applera Corporation-Corporate History and Structure
  • 15.1.2 Molecular Biology Technology and Products
  • 15.1.3 Acquisitions, Partnerships and Collaborations, 2006
  • 15.1.4 Product Portfolio Summary
  • 15.1.5 Real-Time PCR/Genomics Products and Consumables
  • 15.1.6 Real-Time PCR/Genomics New Product Introductions, 2006
  • 15.1.7 End-Users
  • 15.1.8 Distribution Channels
  • 15.1.9 Competition-Gene Expression Products
  • 15.1.10 Competitive Analysis
  • 15.1.11 Business Model
• 15.2 Affymetrix
  • 15.2.1 Corporate History and Structure
  • 15.2.2 Technology
  • 15.2.3 Partnerships and Collaborations
  • 15.2.4 Product Portfolio Summary
  • 15.2.5 Complementary Services
  • 15.2.6 New Product Introductions
  • 15.2.7 End-Users
  • 15.2.8 Distribution Channels
  • 15.2.9 Competition
  • 15.2.10 Competitive Analysis
  • 15.2.11 Business Model
• 15.3 Invitrogen
  • 15.3.1 Corporate History and Structure
  • 15.3.2 Technology
  • 15.3.3 Acquisitions
  • 15.3.4 Partnerships and Collaborations
  • 15.3.5 Product Profile Summary
  • 15.3.6 Gene Expression Product Portfolio
  • 15.3.7 New Product Introductions
  • 15.3.8 End-Users
  • 15.3.9 Distribution Channels
  • 15.3.10 Competition
  • 15.3.11 Competitive Analysis
  • 15.3.12 Business Model
• 15.4 Qiagen
  • 15.4.1 Corporate History and Structure
  • 15.4.2 Technology
  • 15.4.3 Acquisitions, Partnerships and Collaborations
  • 15.4.4 Collaborations and Partnerships
  • 15.4.5 Product Portfolio Summary
  • 15.4.6 Complementary Services
  • 15.4.7 New Product Introductions
  • 15.4.8 End-Users
  • 15.4.9 Distribution Channels
  • 15.4.10 Competition
  • 15.4.11 Competitive Analysis
  • 15.4.12 Business Model
• 15.5 GE Healthcare (Formerly Amersham Biosciences)
  • 15.5.1 Corporate History and Structure
  • 15.5.2 Technology
  • 15.5.3 Product Portfolio Summary
  • 15.5.4 Complementary Services
  • 15.5.5 Genomics New Product Introductions
  • 15.5.6 Amersham Biosciences End-Users
  • 15.5.7 Distribution Channels
  • 15.5.8 Competition
  • 15.5.9 Competitive Analysis
  • 15.5.10 Business Model
• 15.6 Stratagene
  • 15.6.1 Corporate History and Structure
  • 15.6.2 Technology
  • 15.6.3 Acquisitions, Collaborations, Alliances and Partnerships
  • 15.6.4 Product Portfolio Summary-Research Products Division
  • 15.6.5 New Product Introductions
  • 15.6.6 Complementary Services
  • 15.6.7 End-Users
  • 15.6.8 Distribution Channels
  • 15.6.9 Competition
  • 15.6.10 Competitive Analysis
  • 15.6.11 Business Model

Appendix I: Leading Vendor' s Gene Expression Products

Appendix II: Gene Expression Product Groups

Appendix III: Companies Offering Gene Expression Products

LIST OF FIGURES

• Figure 2.1: Gene Expression Process
• Figure 2.2: qRT-PCR Workflow
• Figure 2.3: Microarray Workflow
• Figure 6.1: Gene Expression Market by Region
• Figure 6.2: Researchers Using Gene Expression Technologies Worldwide, 2005
• Figure 6.3: Distribution of Laboratory Workers by Organization in North America
• Figure 6.4: Laboratory Job Function
• Figure 6.5: Product Selection and Purchasing Decision Makers

LIST OF TABLES

• Table 5.1: Microarray Analysis Cost per Sample
• Table 5.2: Cost of qRT-PCR Research Reagents and Systems
• Table 6.1: Five-Year Forecast-Gene Expression Reagents, Instruments
• Table 6.2: RNA Sample Preparation Revenue
• Table 6.3: Forecasted Annual Revenue-qRT-PCR, 2005-2010
• Table 6.4: Forecasted Annual Revenue-Commercial Microarrays, Reagents, Instruments, 2005-2010
• Table 6.5: Forecasted Annual Revenue-Gene Expression Reagents, Instruments, 2005-2010
• Table 6.6: Forecasted Annual Revenue-RNA Sample Preparation, 2005-2010
• Table 6.7: Projected Revenue Growth of Microarrays and Related Products
• Table 6.8: Major Players' Distribution of Revenue by Region, 2005
• Table 6.9: Decision Makers Profile
• Table 9.1: Major Vendors-Gene Expression Reagents and RNA Sample Preparation
• Table 9.2: Vendors' Key Statistics, 2005
• Table 9.3: Vendors' Technology and Products
• Table 11.1: RNA Sample Preparation-Vendors Prices
• Table 11.2: qPCR Kits-Vendor' s Prices
• Table 11.3: Reverse Transcriptase-Vendor' s Prices
• Table 12.1: Distribution Channels
• Table 15.1: Applied Biosystems Revenue, 2005
• Table 15.2: Affymetrix Revenue, 2005
• Table 15.3: Invitrogen Revenue, 2005
• Table 15.4: Qiagen Revenue, 2005
• Table 15.5: GE Healthcare Revenue, 2005
• Table 15.6: Stratagene Revenue, 2005

Genomics World Markets

1. Introduction

• 1.1 Statement of Report
• 1.2 Objectives and Goals of Study
• 1.3 Methodology
• 1.4 Executive Summary
  • 1.4.1 Market Drivers
  • 1.4.2 Market Restraints
  • 1.4.3 Market Size and Growth Projections
• 1.5 What Is a Gene?
• 1.6 Gene Expression
• 1.7 Genetic Variability
• 1.8 The Human Genome Project (HGP)
• 1.9 Gene Databases
• 1.10 Sequencing and Resequencing
• 1.11 RNA Interference (RNAi)
• 1.12 DNA Tags

2. Genomics Technology and Industry

• 2.1 The Development of a Genomics Market
  • 2.1.1 Market Size and Growth Projections
  • 2.1.2 The U.S. Genomics Market
• 2.2 DNA Microarray Technology
  • 2.2.1 Biochips
  • 2.2.2 Photolithography
  • 2.2.3 Instrumentation for DNA Microarray Analysis
  • 2.2.4 Lab-on-a-Chip
  • 2.2.5 DNA Microarrays
• 2.3 Applications of DNA Microarrays
  • 2.3.1 DNA Sequence Analysis
  • 2.3.2 Gene Expression Analysis
  • 2.3.3 Effect of DNA Sequence and Gene Expression Monitoring on the Genomics Market
• 2.4 Bioinformatics
• 2.5 Functional Genomics
  • 2.5.1 Gene Knockdown
  • 2.5.2 Protein-Protein Interactions
  • 2.5.3 Bioinformatics
  • 2.5.4 Strategies of Functional Genomics Companies
  • 2.5.5 Frontiers in Functional Genomics
• 2.6 Comparative Genomics
• 2.7 Pharmacogenomics
• 2.8 Proteomics
• 2.9 Structural Genomics
• 2.10 Disease Targets
  • 2.10.1 Paradigm Shift in Drug Development: The Evolution of Targeted Therapies
  • 2.10.2 Personalized Warfarin Therapy

3. How Genomics Is Revolutionizing Healthcare

• 3.1 Pharmaceutical Applications
• 3.2 Diagnostics
• 3.3 Toxicogenomics
• 3.4 The Market for DNA Microarrays
• 3.5 DNA Chip Technology Competition
• 3.6 Expression Profiling
• 3.7 Gene Sequencing-Advantages of Chip Array Technology
• 3.8 Applied Markets for Genomics
• 3.9 Genomics and the Pharmaceutical Companies
• 3.10 Cancer Markets
• 3.11 Agricultural Markets
  • 3.11.1 Plant Genomics
  • 3.11.2 Food Processing
  • 3.11.3 Animal Husbandry

4. Proprietary Applications and Patents

• 4.1 What is Patentable?
• 4.2 Patents and Litigation

5. Business Analysis

• 5.1 Facilitation and Capitalization of the Convergence of Gene Expression Analysis and Proteomics
• 5.2 Competition
• 5.3 Market Opportunities for Functional Genomics
  • 5.3.1 Metabolic Profiling
  • 5.3.2 Anti-Fungal Targets
  • 5.3.3 Nutrition
  • 5.3.4 Crop Production
• 5.4 The Highly-Competitive Nature of the Genomics Industry
  • 5.4.1 First-Generation Biotech
  • 5.4.2 Second-Generation Genomics Companies
  • 5.4.3 Next-Generation DNA Sequencing Companies
• 5.5 Strategic Alliances

6. Genomics Company Profiles

• 6.1 Affymetrix, Inc.
• 6.2 Agendia
• 6.3 Agilent Technologies, Inc.
• 6.4 Applied Biosystems Group
• 6.5 Bayer, AG
• 6.6 Biotage
• 6.7 Caliper Life Sciences
• 6.8 Celera Group
• 6.9 Cepheid
• 6.10 CLC bio
• 6.11 Clinical Data, Inc.
• 6.12 CuraGen Corporation
• 6.13 Cytocell Ltd.
• 6.14 diaDexus, Inc.
• 6.15 Enzo Biochem, Inc.
• 6.16 Exiqon A/S
• 6.17 GE Healthcare
• 6.18 Gene Link, Inc.
• 6.19 Gene Logic, Inc.
• 6.20 Genentech, Inc.
• 6.21 Genisphere, Inc.
• 6.22 Genomatix Software, Inc.
• 6.23 Genomic Solutions, Inc.
• 6.24 Gen-Probe, Inc.
• 6.25 Harvard Bioscience, Inc.
• 6.26 Helicos Biosciences Corporation
• 6.27 Human Genome Sciences, Inc.
• 6.28 Illumina, Inc.
• 6.29 Interleukin Genetics
• 6.30 LI-COR Biosciences
• 6.31 Luminex Corporation
• 6.32 Millennium Pharmaceuticals, Inc.
• 6.33 Monogram Biosciences, Inc.
• 6.34 Motorola, Inc.
• 6.35 MWG Biotech AG
• 6.36 Myriad Genetics, Inc.
• 6.37 Nanogen, Inc.
• 6.38 Nuvelo, Inc.
• 6.39 Orchid Cellmark
• 6.40 Pacific Biosciences, Inc.
• 6.41 QIAGEN, Inc.
• 6.42 Roche Diagnostics
• 6.43 Sequenom, Inc.
• 6.44 Third Wave Technologies, Inc.
• 6.45 Verenium Corporation
• 6.46 Visigen Technologies, Inc.
• 6.47 Brief Profiles of Companies Marketing Personalized Genomics Products
• 6.47.1 23andMe, Inc.
• 6.47.2 deCODE Genetics, Inc.
• 6.47.3 Navigenics, Inc.
• 6.48 Brief Profiles of Other Selected Genomics Firms
• 6.48.1 Aber Genomic Computing
• 6.48.2 Spotfire, Inc.

7. Genomics Challenges and Growth Factors

• 7.1 Market Drivers
  • 7.1.1 Product Pipeline: Need for More Drug Candidates
  • 7.1.2 Need for Increased Research and Development Productivity
• 7.2 A Genomics Market Bottleneck-Bioinformatics
• 7.3 Strategic Recommendations-Market Opportunities
  • 7.3.1 More Comprehensive Tools Are Needed
  • 7.3.2 Resolving Bottlenecks in Functional Genomics Market
• 7.4 Key Trends of Recent Mergers and Acquisition Deals
• 7.5 Chemogenomics
• 7.6 Pharmacogenomics
• 7.7 Biomarkers
• 7.8 Additional Genomics Market Opportunities

8. Bioinformatics

• 8.1 Types of Data and Bioinformatics Applications
  • 8.1.1 Validated Core Modeling Technology
  • 8.1.2 Broad Applicability
  • 8.1.3 Data Management Compliant with Industry Standards
  • 8.1.4 Open Architecture
  • 8.1.5 Ease of Use
  • 8.1.6 Increased Access
• 8.2 Functions of Informatics Software
  • 8.2.1 Data Management
  • 8.2.2 Transformation of Data into Knowledge
  • 8.2.3 Collaboration Among Researchers
  • 8.2.4 Interface for Online Data Sources
• 8.3 Target Markets for Informatics Software
  • 8.3.1 Pharmaceutical Companies
  • 8.3.2 Biotechnology Companies
  • 8.3.3 Academic and Government Research Institutions
  • 8.3.4 Agricultural, Environmental and Industrial Biotechnology Companies
• 8.4 Products of Bioinformatics
  • 8.4.1 Sequences and Structure of Genes and Proteins
  • 8.4.2 3-D Molecular Structures
  • 8.4.3 Genome Structures and Functions
  • 8.4.4 Bibliographic Data
• 8.5 Bioinformatics Processes
• 8.6 Informatics Tools and Functionalities
  • 8.6.1 Sequence to Structure
  • 8.6.2 Lead Identification and Optimization
  • 8.6.3 Development and Formulation
  • 8.6.4 Improving Materials and Processes in the Chemicals Industry
  • 8.6.5 Other Materials-Based Industries
• 8.7 Role of Bioinformatics in the Value Chain
• 8.8 Bioinformatics Market Segments
  • 8.8.1 Database
  • 8.8.2 Hardware
  • 8.8.3 Software
  • 8.8.4 Bioinformatics Services
• 8.9 Bioinformatics Business Models
  • 8.9.1 Changing Business Models
  • 8.9.2 Selected Business Strategies

Glossary

INDEX OF FIGURES

• Figure 2.1: Major Areas of Functional Genomics and Their Relationship to Bioinformatics and Industry
• Figure 8.1: Role of Bioinformatics in the Biotechnology Value Chain

INDEX OF TABLES

• Table 2.1: Genomics Sector Global Market Size, 2001 to 2010
• Table 2.2: Companies Marketing DNA Microarray Software
• Table 2.3: Selected Competitors in the DNA Microarray Market
• Table 2.4: Companies Offering DNA Sequencing Products
• Table 2.5: Competitors in the SNP-Genotyping Segment
• Table 2.6: Companies that Market MAQC-tested Gene Expression Microarrays
• Table 2.7: Worldwide Market for Bioinformatics, 2005 to 2010
• Table 2.8: Selected Companies Marketing New Functional Genomics Tools
• Table 3.1: Genomics Pharmaceutical Market Sector Leaders and Promising Newcomers
• Table 3.2: Summary of Assays for HIV Viral Load Testing
• Table 3.3: Global Market for HIV Diagnostic Testing, 2000 to 2012
• Table 3.4: Summary of Molecular Diagnostics Testing
• Table 3.5: Global Market for Molecular Diagnostics Testing, 2000 to 2012
• Table 3.6: U.S. Market for Molecular Diagnostics Testing, 2004 to 2012
• Table 3.7: Applied Markets for Genomics
• Table 3.8: Competitors in the Field of Identity Genomics Testing
• Table 3.9: Opportunities for Molecular-Targeting Therapeutics for Cancer
• Table 3.10: Emerging Companies in the Anti-Cancer Sector
• Table 8.1: Data Source and Bioinformatic Investigations
• Table 8.2: Bioinformatics Activities, Subactivities and Key Players

Microarray Markets

1. Overview

• 1.1 Statement of Report
• 1.2 About This Report
• 1.3 Scope of the Report
• 1.4 Objectives
• 1.5 Methodology
• 1.6 Executive Summary

2. Overview of Microarrays

• 2.1 History of Microarrays
• 2.2 Genomics and Proteomics
  • 2.2.1 Genetic Variability and Disease
• 2.3 General Theory of Microarrays
• 2.4 DNA Microarrays
• 2.5 Protein Microarrays
• 2.6 Tissue Microarrays

3. DNA Microarrays

• 3.1 Advantages and Drivers
• 3.2 Limitations and Barriers to Commercialization
• 3.3 DNA Microarray Technology Platforms
  • 3.3.1 Reasons Why Researchers Utilize DNA Microarrays
  • 3.3.2 Factors for Difficulties Applying DNA Microarrays Technology
• 3.4 Key Attributes of DNA Microarray Software
• 3.5 Applications
• 3.6 Future Directions for DNA Microarray Technology
  • 3.6.1 High-Throughput Array Technology
  • 3.6.2 Emerging Microarray Trends
  • 3.6.3 Emerging Microarray Applications
  • 3.6.4 Key Points for Developing Microarray Based Applications
• 3.7 Competitive Landscape for DNA Microarrays

4. Protein Microarrays

• 4.1 Critical Factors for Microarray Content
• 4.2 Key Findings on Use of Microarrays
• 4.3 Advantages and Drivers
• 4.4 Limitations and Barriers to Commercialization
• 4.5 Key Experimental Parameters of Protein Microarray Technology for Current and Future Users
• 4.6 Reasons Why Researchers Utilize Protein Microarrays
• 4.7 Factors for Adoption of Protein Microarrays Technology
• 4.8 Top Suppliers of Protein Microarray Slides and Products
• 4.9 Factors that Influence Sale Decisions
• 4.10 Future Innovations in Protein Microarray Technology

5. Current DNA Microarrays

• 5.1 Key Players
  • 5.2.1 Microarray-Based Commercial Genotyping Activity
  • 5.2.2 Location Analysis
• 5.3 Future Innovations in DNA Microarray Technology

6. Current Protein Microarrays

• 6.1 Protein Profiling Microarrays-Antibody Arrays
• 6.2 Protein Profiling Microarrays-Reverse Phase Microarrays
• 6.3 Multiplex Sandwich Microarrays-Planar
• 6.4 Multiplex Sandwich Immunoassays-Bead Based
• 6.5 Microarrays for Protein Function Studies
• 6.6 High Growth Applications
  • 6.6.1 Cytokine Arrays
  • 6.6.2 Whole Proteome Arrays
  • 6.6.3 Microarray-Based Commercial Genotyping Activity
    • 6.6.3.1 Microarray-Based Genotyping Applications
    • 6.6.3.2 Microbial Applications
    • 6.6.3.3 The Market for Microbial Genotyping Products
    • 6.6.3.4 Comparative Genomic Hybridization (CGH)
  • 6.6.4 ChIP-on-Chip Analysis

7. Technology

• 7.1 Production of Microarrays
• 7.2 2-D Versus 3-D Technology
• 7.3 Substrates and Surface Chemistries
• 7.4 Detection Methods
• 7.5 Instruments
• 7.6 Data Management and Informatics in Gene Expression

8. Applications

• 8.1 DNA Microarrays in Gene Expression
• 8.2 DNA Microarrays in SNP Analysis
• 8.3 DNA Microarrays in Cancer
• 8.4 Protein Expression
  • 8.4.1 Cytokine Applications
  • 8.4.2 Protein Function
  • 8.4.3 Protein-Protein Interactions
• 8.5 Target /Biomarker Discovery
• 8.6 Drug Discovery and Development (Gene and Protein Microarrays)
• 8.7 Clinical Diagnostics (Gene and Protein Microarrays)
• 8.8 RNA Microarrays
• 8.9 Oligo Microarrays
• 8.10 Yeast Microarrays
• 8.11 Antibody Arrays
• 8.12 Arrays for Toxicogenomics

9. The Commercial Opportunity for Microarrays

• 9.1 Market Drivers for Microarrays
• 9.2 Market Restraints for Microarrays
• 9.3 Key Players
• 9.4 Market Size, Strategic Trends and Competitive Landscape for Protein Arrays
• 9.5 Marketing and Distribution
• 9.6 Protein Arrays Market Analysis
• 9.7 Genes Associated with Major Diseases
• 9.8 Software and Data Analysis
  • 9.8.1 Supplier of DNA Microarray Analysis Software
  • 9.8.2 Satisfaction with Software Features
  • 9.8.3 Satisfaction with Software
  • 9.8.4 Supplier Factors in Software Purchase Decision
  • 9.8.5 Suppliers' Role in Improving Data Sharing for DNA Microarrays

10. Company Profiles

• 10.1 Manufacturers

LIST OF FIGURES

• Figure 6.1: Cytokines and Growth Factors: Sources of Microarrays for Cytokine Research
• Figure 8.1: Microbial Genotyping: Applications for DNA Microarrays
• Figure 8.2: Source of Variation in Microarray Data
• Figure 8.3: Toxicogenomics: DNA Microarrays

LIST OF TABLES

• Table 3.1: Microarray Product Revenue: Arrays, Reagents and Instruments, 2005 and 2010
• Table 3.2: Microarray Market Drivers
• Table 3.3: Microarray Market Barriers
• Table 3.4: Unit Pricing of DNA Microarrays, 2000-2010
• Table 3.5: Steps in the Design and Implementation of a DNA Microarray Experiment
• Table 3.6: Microarray Applications
• Table 3.7: List of DNA Array Manufacturers
• Table 4.1: Critical Factors for Microarray Content
• Table 4.2: Top Three Suppliers of Treated Protein Microarray Surfaces for Self-Printing
• Table 4.3: Top Suppliers of Commercially Available Protein Microarrays
• Table 4.4: Top Suppliers of Protein Microarray Readers
• Table 5.1: Affymetrix Sales of Probe Arrays, 2000-2007
• Table 5.2: Affymetrix Total Product Sales, 1999-2007
• Table 5.3: Affymetrix Instrument Sales, 2000-2007
• Table 6.1: Microarray Genetic Testing
• Table 6.2: ChIP-on-Chip Microarray Market Size Projections, 2005-2011
• Table 8.1: Applications of Biochips by Class
• Table 8.2: Diagnostics Microarray Market Size Projections, 2005-2011
• Table 8.3: HTS Microarray Market Size Projections, 2005-2011
• Table 8.4: Pharmacogenomics Microarray Market Size Projections, 2005-2011
• Table 8.5: Toxicology Screening Microarray Market Size Projections, 2005-2011
• Table 8.6: Expression Profiling Microarray Market Size Projections, 2005-2011
• Table 9.1: Market Share of Microarray Products, 2006
• Table 9.2: Affymetrix Product Sales
• Table 9.3: Leading Microarray Companies
• Table 9.4: Worldwide Microarray Market Size, 2004-2012
• Table 9.5: Microarray Market Share by Technology Type
• Table 9.6: DNA Microarray U.S. Market Size, 2005-2011
• Table 9.7: DNA Microarray Worldwide Market Size, 2002-2011
• Table 9.8: Biochip Market by Usage, 2003 and 2007

Personalized Medicine

1. Overview

• 1.1 Statement of Report
• 1.2 Scope of this Report
• 1.3 Methodology
• 1.4 Executive Summary

2. The Case for Pharmacogenomics and Personalized Medicine: Biology, Approaches, Pipeline and Regulatory Trends

• 2.1 Scope of this Section
• 2.2 Introduction to Pharmacogenomics/Personalized Medicine
• 2.3 The Compelling Case for Personalized Medicine
• 2.4 The Process of Drug Metabolism and Implications for Pharmacogenomics/Personalized Medicine
• 2.5 Examples of Personalized Medicine
  • 2.5.1 Herceptin
  • 2.5.2 Ziagen
  • 2.5.3 Iressa
  • 2.5.4 Erbitux
• 2.6 Personalized Medicine Product Pipeline
• 2.7 The Personalized Medicine Coalition
• 2.8 Regulatory Trends and Guidelines in the Personalized Medicine Space
• 2.9 FDA Approved Agendia' s MammaPrintR Diagnostic-The First IVDMIA to be Approved
• 2.10 A Changing Regulatory Landscape for Personalized Medicine
• 2.11 Patenting Personalized Medicine
  • 2.11.1 U.S. Supreme Court Dismisses LabCorp Appeal
• 2.12 The Leading Edge of Personalized Medicine: Specific Examples of Clinical Situations Where Personalized Medicine is Appropriate and Being Used
  • 2.12.1 EGFR Assay
  • 2.12.2 Individualized Warfarin Therapy
  • 2.12.3 UGT1A1 Molecular Assay for Camptosar
  • 2.12.4 Response to Gleevec in Gastrointestinal Stromal Tumors
  • 2.12.5 LabCorp, ARCA Personalized Medicine Deal for Cardiovascular Diseases
  • 2.12.6 Osmetech Licenses Epidauros Biotechnologie AG CYP2D6 Biomarker to Push into Pharmacogenomics

3. Pharmacogenomics/Personalized Medicine: Qualitative and Quantitative Market Analysis

• 3.1 Scope of this Section
• 3.2 Market Analysis of Molecular Diagnostics as it Relates to Pharmacogenomics/Personalized Medicine
• 3.3 Snapshot of Diagnostics Industry Structure
• 3.4 The Case for Theranostics (Therapeutic/Companion Diagnostic)
• 3.5 Classification of Diagnostics by Risk
• 3.6 Personalized Medicine Market Analysis-Market Survey Data Characterizing the Qualitative and Quantitative Industry Parameters
• 3.7 Segmentation of the Personalized Medicine Marketplace
• 3.8 Timeline for Impact of Various Segments in Personalized Medicine
• 3.9 Challenges for Personalized Therapeutics Development
• 3.10 Molecular Diagnostics Technology Platforms and Their Impact on Personalized Medicine
• 3.11 Macro Trends in Personalized Medicine
• 3.12 Personalized Medicine: Industry SWOT Analysis

4. Company Profiles

• 4.1 Abbott Molecular, Inc./Vysis
• 4.2 Affymetrix, Inc.
• 4.3 Agendia
• 4.4 Celera Diagnostics
• 4.5 Cepheid
• 4.6 Clinical Data, Inc.
• 4.7 Dakocytomation
• 4.8 deCODE Genetics
• 4.9 DNA Direct, Inc.
• 4.10 DxS Ltd.
• 4.11 Exact Sciences Corp.
• 4.12 Exagen Diagnostics, Inc.
• 4.13 Gen-Probe
• 4.14 Genelex Corp.
• 4.15 Gene Logic, Inc.
• 4.16 Genentech, Inc.
• 4.17 Genomic Health, Inc.
• 4.18 Genzyme Genetics
• 4.19 Illumina
• 4.20 Luminex Corporation/Tm Biosciences
• 4.21 Monogram Biosciences
• 4.22 Myriad Genetics, Inc.
• 4.23 Nanogen
• 4.24 Osmetech plc
• 4.25 Perlegen Sciences, Inc.
• 4.26 PGxl Laboratories
• 4.27 Prometheus Laboratories, Inc.
• 4.28 Roche Diagnostics
• 4.29 Siemens Medical Solutions Diagnostics
• 4.30 Target Discovery, Inc.
• 4.31 Third Wave Technologies
• 4.32 Ventana Medical Systems
• 4.33 XDx, Inc.

Appendix 1: Qualitative Market Responses

LIST OF FIGURES

• Figure 2.1: Phase I and II Processes of Drug Metabolism
• Figure 2.2: Human Phase I Enzymes
• Figure 2.3: Human Phase II Enzymes
• Figure 2.4: Hepatic Distribution of Human CYP450
• Figure 2.5: Relative Contribution of CYP450 Enzymes to Drug Metabolism
• Figure 2.6: Genetic Components Determine Drug Metabolism
• Figure 3.1: From Genetic Content to Personalized Medicine
• Figure 3.2: The Lopsided Remuneration for Diagnostics
• Figure 3.3: Breakout of the Molecular Diagnostics Marketplace
• Figure 3.4: Molecular Diagnostics Market Segmentation
• Figure 3.5: Molecular Diagnostics Market Segmentation by Technology
• Figure 3.6: Market Survey Respondent Demographics
• Figure 3.7: Breakout of the Respondent Pool by Affiliation
• Figure 3.8: Segmentation of the Personalized Medicine Market
• Figure 3.9: Personalized Medicine Market Drivers
• Figure 3.10: Challenges in the Personalized Medicine Space

LIST OF TABLES

• Table 2.1: Personalized Medicine at the Nexus Point
• Table 2.2: Percentage of Non-Responders in Various Drug Classes
• Table 2.3: High Profile Drug Withdrawals from the Marketplace
• Table 2.4: Drug Metabolism Drives Drug Efficacy/Toxicity
• Table 2.5: Population Frequency of the Various Cytochromes
• Table 2.6: List of Personalized Medicine Tests
• Table 2.7: Personalized Medicine Product Pipeline
• Table 2.8: Marketed Personalized Therapies, 2006
• Table 2.9: Current Targets, Drugs and Disease Areas Classified by their Clinical Applications
• Table 3.1: Areas in Personalized Medicine-Timeline of Impact
• Table 3.2: Impact of Personalized Medicine on Various Therapeutic Areas
• Table 3.3: Hurdles in Personalized Medicine Development in Various Therapeutic Areas
• Table 3.4: Various Molecular Diagnostics Technologies: Timeline for Impact
• Table 3.5: Various Molecular Diagnostics Technologies: Impact on Different Therapeutic Areas in Personalized Medicine
• Table 3.6: Various Molecular Diagnostics Technologies: Technical Challenges in the Deployment for Personalized Medicine
• Table 3.7: Market Opportunities in Personalized Medicine
• Table 3.8: Challenges for Market Adoption of the Various Personalized Medicine Tests
• Table 3.9: Personalized Medicine Industry SWOT

Pharmacogenomics for Clinical Use and in Drug Development

1. Overview

• 1.1 Statement of Report
• 1.2 Objectives of this Report
• 1.3 Scope of the Study
• 1.4 Methodology
• 1.5 Executive Summary

2. Introduction

• 2.1 Pharmacogenomic Testing Overview
• 2.1.1 Clinical Applications
• 2.1.2 Technologies for Pharmacogenomic Diagnostic Tools
• 2.1.3 Drug and Diagnostic Combinations
• 2.1.4 Economic Impact of Healthcare Costs
• 2.2 Genetic Variation among Individuals
  • 2.2.1 Population Genomics
  • 2.2.2 SNPs and Haplotypes
  • 2.2.3 HapMap
    • 2.2.3.1 The International HapMap Project
    • 2.2.3.2 HapMap Participants and Funding Sources
• 2.3 Drug Metabolism
  • 2.3.1 Adverse Drug Reactions (ADRs)
  • 2.3.2 Drug-Test Combinations
• 2.4 Impact of Pharmacogenomics
  • 2.4.1 How Will Gene Variation Be Used in Predicting Drug Response?
  • 2.4.2 How Will Drug Development and Testing Benefit from Pharmacogenomics?
  • 2.4.3 Advantages of Pharmacogenomics
  • 2.4.4 The Diagnostics-Therapeutics Fusion
  • 2.4.5 Potential Challenges
  • 2.4.6 Poor Metabolizer Phenotype Testing
  • 2.4.7 Drug Repositioning
• 2.5 Pharmacogenomic Tests
  • 2.5.1 CYP2D6
  • 2.5.2 CYP2C19 and CYP2C9
  • 2.5.3 CYP3A4 and CYP3A5 Genotyping
  • 2.5.4 CYP1A2 and CYP2B6
  • 2.5.5 NAT2, DPD, and UGT1A1
• 2.6 HercepTest
• 2.7 Drivers of Pharmacogenomic Testing
• 2.8 Pharmacogenomics and Drug Discovery
  • 2.8.1 Business Implications of Pharmacogenomics in Drug Discovery
  • 2.8.2 Impact of Pharmacogenomics on Drug Sales
  • 2.8.3 Pressure to Optimize Drug Discovery Drives Use of Pharmacogenomics

3. Pharmacogenomic Testing Market: Size, Growth and Share

• 3.1 Global Pharmacogenomic Testing Markets by Technology Segments
  • 3.1.1 Market Structure
  • 3.1.2 Market Drivers in the Pharmacogenomic Diagnostics Testing Sector
  • 3.1.3 Market Restraints in Pharmacogenomic Diagnostic Testing Segment
  • 3.1.4 Principal Market Segments for Genomics Testing
    • 3.1.4.1 Diagnostic Testing
    • 3.1.4.2 Pharmacogenomic Testing
    • 3.1.4.3 SNP Identification
  • 3.1.5 Key Players in the Pharmacogenomic Diagnostics Testing Segment
  • 3.1.6 Pharmacogenomic Testing Sector Analysis
• 3.2 U.S. Pharmacogenomic Testing Market
  • 3.2.1 Market Overview
  • 3.2.2 Diagnostic Testing Categories
• 3.3 European Pharmacogenomic Diagnostic Testing Market
• 3.4 Japanese Diagnostic Testing Market

4. Pharmacogenomic Disease Markers

• 4.1 SNPs
  • 4.1.1 SNP Identification Market
  • 4.1.2 Overview of SNP Identification
  • 4.1.3 Strategies for SNP Identification
  • 4.1.4 Candidate Gene Selection
  • 4.1.5 Whole-Genome Linkage Disequilibrium Mapping
  • 4.1.6 SNP Databases
  • 4.1.7 Computational Tools for SNP Identification
  • 4.1.8 SNPbrowser, Applied Biosystems
  • 4.1.9 Progeny Suite, Progeny Software, LLC
  • 4.1.10 Sentrix Array Matrix, Illumina
  • 4.1.11 Third Wave Technologies (a Hologic Company)
• 4.2 Predictive Pharmacogenomics
  • 4.2.1 Cancer Testing
  • 4.2.2 Breast Cancer
  • 4.2.3 Melanoma
  • 4.2.4 Colon Cancer
  • 4.2.5 Predictive Cancer Testing Market Size
  • 4.2.6 Prostate Cancer
  • 4.2.7 Lung Cancer
  • 4.2.8 Acute Myelocytic Leukemia (AML)
  • 4.2.9 Cystic Fibrosis
  • 4.2.10 Genetic Test for Cardiac Ion Channel Mutations (Cardiac Channelopathies)
  • 4.2.11 Cardiac Transplants
  • 4.2.12 Thiopurine S-methyltransferase (TPMT) Genetic Test
  • 4.2.13 CARING Study
  • 4.2.14 Vilazodone
  • 4.2.15 STRENGTH Trials (Statin Response Examined by Genetic HAP Markers)
  • 4.2.16 HIV and AIDS
  • 4.2.17 Herceptin and Tykerb
  • 4.2.18 Asthma
  • 4.2.19 Hepatitis C Viral Load
• 4.3 Examining the Impact of Pharmacogenomics in Specific Disease Application
  • 4.3.1 The Impact of Pharmacogenomics in Bipolar and Other Psychiatric Disorders
  • 4.3.2 Pharmacogenomics in Warfarin Treatment
  • 4.3.3 Pharmacogenomics and Breast Cancer Treatment
  • 4.3.4 Pharmacogenomics of Depression
    • 4.3.4.1 Tricyclic Antidepressants
    • 4.3.4.2 Serotonin Re-uptake Inhibitors
    • 4.3.4.3 Mirtazapine and Venlafaxine
    • 4.3.4.4 Nefazodone, Moclobemide, Reboxetine and Trazodone
  • 4.3.5 Pharmacogenomics of Cardiovascular Disease
    • 4.3.5.1 Beta-blockers
    • 4.3.5.2 Angiotensin II Type 1 Receptor Antagonists and AT1 Receptor Antagonists (Sartans)
  • 4.3.6 Pharmacogenomics of Thromboembolic Disorders
    • 4.3.6.1 Warfarin
    • 4.3.6.2 Acenocoumarol
    • 4.3.6.3 Phenprocoumon
• 4.4 Gene Chips to Detect Cytochrome Variations
  • 4.4.1 AmpliChip CYP450-Roche Diagnostics
  • 4.4.2 GeneChip System-Affymetrix
  • 4.4.3 NanoChip Molecular Biology Workstation-Nanogen, Inc.

5. Pharmacogenomic Testing: Development Issues

• 5.1 Adoption of Pharmacogenomic Testing
  • 5.1.1 Pharmacogenomics Gatekeepers
    • 5.1.1.1 Industry
      • 5.1.1.1.1 Use of Pharmacogenomics in Drug Development
      • 5.1.1.1.2 Co-development of Pharmacogenomics Diagnostics and Drugs
    • 5.1.1.2 FDA as a Gatekeeper of Pharmacogenomics
• 5.2 Factors Influencing the Integration of Pharmacogenomics into Clinical Trials
• 5.3 Moderators of Growth
  • 5.3.1 Classification of Extensive vs. Poor Metabolizer
  • 5.3.2 Genetic Testing
  • 5.3.3 Cost-Benefit of Pharmacogenomic Testing
  • 5.3.4 Workforce Issues
  • 5.3.5 Reimbursement
  • 5.3.6 New CPT Test Codes and Payment Amounts
  • 5.3.7 CMS and Other Third-party Payers
    • 5.3.7.1 Reimbursement Challenges to Pharmacogenomic Testing
    • 5.3.7.2 CMS Regulatory Responsibilities
    • 5.3.7.3 Costs Associated with Pharmacogenomic Testing
• 5.4 Clinical Guidelines and Pharmacogenomic Testing
• 5.5 Good Laboratory Practice (GLP)
• 5.6 Quality Assurance Issues
  • 5.6.1 Criteria Required to Establish a Genomic Test for Clinical Use
  • 5.6.2 Microarrays in Clinical Diagnostic Use
• 5.7 Pre-therapeutic Pharmacogenomic Testing
• 5.8 Regulatory Requirements
• 5.9 Screening
• 5.10 Cost of Phenotyping vs. Genotyping
• 5.11 Pharmacogenomic Tests: New Product Development
• 5.12 Underutilization of Pharmacogenomic Tests

6. Business Trends in the Industry

• 6.1 Pharmacogenomic Initiatives within Pharmaceutical Companies
• 6.2 Pharmacogenomic Testing Growth Factors
• 6.3 Acquisition, License Agreements, Internal Development and Partnerships
• 6.4 Product Testing Depth in Pharmacogenomic Testing
• 6.5 Government Regulation
  • 6.5.1 U.S. Regulations
  • 6.5.2 U.K. Regulations
  • 6.5.3 E.U. Regulations
  • 6.5.4 Japanese Regulations
• 6.6 Increased Market Penetration in Pharmacogenomic Testing
• 6.7 Legal Issues
  • 6.7.1 Federal Policy History
  • 6.7.2 State Policy History
  • 6.7.3 Federal Anti-Discrimination Laws and How They Apply to Genetics
    • 6.7.3.1 The Genetic Information Nondiscrimination Act of 2008 (GINA)
  • 6.7.4 Prescription Drug User Fee Act (PDUFA)
  • 6.7.5 Liability Concerns for Pharmacogenomics Drug and Diagnostic Developers
• 6.8 Barriers to Growth
• 6.9 Drivers of Growth
• 6.10 Product Launches and Developments
• 6.11 Investment Parameters for Diagnostic Companies
• 6.12 Key Elements of the Pharmaceutical Value Chain
• 6.13 An Evaluation of Successful Pharmacogenomic Business Models
• 6.14 Ethical Considerations for Pharmacogenomic Applications
• 6.15 Drug Repositioning Services
• 6.16 Patent Protection of Pharmacogenomic Technology
• 6.17 FDA Product Submission and Review Process
• 6.18 FDA Pipeline for Pharmacogenomic Tests
• 6.19 Adaptive Clinical Trial Design

7. Important Technology Trends in Pharmacogenomics

• 7.1 Trends in Pharmacogenomic Testing
  • 7.1.1 Toxicogenomics
• 7.2 Drug Metabolism
• 7.3 Personalized Medicine: the Genomic and Proteomic Approach
• 7.4 Biomarkers
  • 7.4.1 Cancer
    • 7.4.1.1 Leukemia: Gleevec and Dasatinib (BMS-354825)
    • 7.4.1.2 Gefitinib (Iressa)
    • 7.4.1.3 Colorectal Cancer
• 7.5 Cardiovascular Drugs
  • 7.5.1 Arrhythmia
  • 7.5.2 Hypertension
  • 7.5.3 Hyperlipidemia
  • 7.5.4 Myocardial Infarction
  • 7.5.5 Heart Failure
• 7.6 Future Developments
  • 7.6.1 GSK' s Pharmacogenomic Program
  • 7.6.2 Roche' s Biomarker Strategy
  • 7.6.3 Hypertension Markets
  • 7.6.4 Expression Data to Integrate Pharmacology and Chemistry Data
  • 7.6.5 Metabolomics
  • 7.6.6 Theranostics

8. Overview and Conclusions

• 8.1 The Unrealized Promise of Pharmacogenomics
• 8.2 The New Drug Pipeline
• 8.3 Pharmacogenomics and Regulation
• 8.4 Pharmacogenomics and Reimbursement
• 8.5 Key Considerations for Realizing the Promise of Pharmacogenomics
• 8.6 Development of Easy to Use Point of Care Pharmacogenomic Tests
• 8.7 Development of Pharmacogenomic Tests during Drug Development
• 8.8 Pharmacogenomics' Impact on Commercial Strategies
• 8.9 Pharmacogenomics' Impact on the Blockbuster Model of Drug Development
• 8.10 Pharmacogenomics' Impact on Clinical Trials
• 8.11 Pharmacogenomic Business Models
• 8.12 Structure of Pharmacogenomic Deals and Alliances
• 8.13 Challenges to Pharmacogenomics

9. Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Affymetrix
• 9.3 Agilent Technologies, Inc.
• 9.4 Ambry Genetics
• 9.5 ARCA Biopharma, Inc.
• 9.6 Asper Biotech
• 9.7 AstraZeneca
• 9.8 Bayer
• 9.9 BioTrove, Inc.
• 9.10 Bristol-Myers Squibb
• 9.11 Celera Group
• 9.12 Clinical Data
• 9.13 CombinatoRx, Inc.
• 9.14 Complement Genomics Ltd.
• 9.15 Covance Inc.
• 9.16 CuraGen Corporation
• 9.17 Cypress Bioscience, Inc.
• 9.18 Dako (formerly DakoCytomation)
• 9.19 deCODE Genetics
• 9.20 DNAPrint Genomics
• 9.21 DxS
• 9.22 EraGen Biosciences
• 9.23 EXACT Sciences
• 9.24 Expression Analysis
• 9.25 FivePrime Therapeutics
• 9.26 GE Healthcare
• 9.27 Gene Express, Inc.
• 9.28 GeneGO Inc.
• 9.29 Genelex Corporation
• 9.30 Genentech
• 9.31 Genizon Biosciences Inc.
• 9.32 Genomic Health
• 9.33 Gentris
• 9.34 Genzyme
• 9.35 GlaxoSmithKline
• 9.36 g-Nostics Ltd.
• 9.37 Hologic
• 9.38 Human Genome Sciences
• 9.39 Illumina
• 9.40 Incyte, Inc.
• 9.41 InterGenetics Inc.
• 9.42 Interleukin Genetics
• 9.43 Iris BioTechnologies Inc.
• 9.44 Johnson & Johnson
• 9.45 Lab21
• 9.46 Life Technologies Corporation
• 9.47 Luminex Corp.
• 9.48 MediBIC Group
• 9.49 Melior Discovery Inc.
• 9.50 Merck & Co.
• 9.51 Merck Serano
• 9.52 Millennium Pharmaceuticals
• 9.53 Monogram Biosciences, Inc.
• 9.54 Myriad Genetics, Inc.
• 9.55 Nanogen
• 9.56 Nanosphere
• 9.57 Nitromed
• 9.58 Ocimum Biosolutions
• 9.59 Orchid Cellmark
• 9.60 Ore Pharmaceuticals
• 9.61 PharmaSeq
• 9.62 Prediction Sciences
• 9.63 Predictive Biosciences
• 9.64 Prometheus Laboratories
• 9.65 Progeny Software, LLC
• 9.66 Roche Diagnostics
• 9.67 Response Genetics, Inc.
• 9.68 Sequenom
• 9.69 SimuGen Ltd.
• 9.70 Sosei Group Corporation
• 9.71 Transgenomic, Inc.
• 9.72 TrimGen Corp.
• 9.73 Tripos International
• 9.74 Vertex Pharmaceuticals
• 9.75 VIA Pharmaceuticals, Inc.
• 9.76 Warnex
• 9.77 Wyeth
• 9.78 XDx, Inc.

INDEX OF FIGURES

• Figure 2.1: Roche AmpliChip
• Figure 2.2: FDA Approval Rates for NME Drug Applications vs. R&D Expenditures, 1998-2008
• Figure 2.3: Steps Involved in Bringing a Drug to Market
• Figure 2.4: CYP2C9
• Figure 6.1: Total Spending on Healthcare in the U.S., 1960-2008
• Figure 6.2: The Healthcare Dollar, 2008

INDEX OF TABLES

• Table 1.1: The Success of Pharmacogenomics: Drugs that Utilize Companion Tests, 2008
• Table 2.1: The Difference between Pharmacogenomics and Pharmacogenetics
• Table 2.2: Clinical Applications of Diagnostic Pharmacogenomic Testing
• Table 2.3: Comparison of New Molecular Entity Outcomes for FDA and EMEA (Jan 2006 - October 2008)
• Table 2.4: Timeline for Development of Companion Diagnostics
• Table 2.5: Valid Genomic Biomarkers in the Context of FDA-Approved Drug Labels
• Table 2.6: Potential Benefits of Biomarkers as Companion Diagnostics in Drug Development
• Table 2.7: Groups Participating in the International HapMap Project
• Table 2.8: High-Profile Drug Withdrawals from the Marketplace
• Table 2.9: Response Rates of Patients to a Major Drug for Selected Therapeutic Areas
• Table 2.10 Factors That Determine a Successful Pharmacogenomic Test
• Table 2.11: Pharmacogenomics' Influence on Drug Sales
• Table 2.12: Pharmacogenomics' Effect on Maximizing R&D Productivity
• Table 2.13: Prevalence of Metabolically-Active Enzymes
• Table 2.14: Pharmacogenomics in Phase II and Phase III Trials
• Table 2.15: Drug Testing
• Table 2.16: Factors Affecting Variability in Individual Response to Drug Therapy
• Table 2.17: CYP2D6 Characteristics
• Table 2.18: CYP2D6 Metabolism of Drug Types
• Table 2.19: CYP2C19
• Table 2.20: CYP2C19 Metabolism of Drug Types
• Table 2.21: CYP2C9 Characteristics
• Table 2.22: CYP2C9 Metabolism of Drug Types
• Table 2.23: CYP3A4/5/7 Metabolism of Drug Types
• Table 2.24: CYP1A2 Metabolism of Drug Types
• Table 2.25: CYP2B6 Metabolism of Drug Types
• Table 2.26: Drivers of Pharmacogenomic Testing
• Table 2.27: Markets for Pharmacogenomic Testing
• Table 3.1: Worldwide Pharmacogenomic Market Size by Technology Segments, 2004-2012
• Table 3.2: Total Pharmacogenomic Testing Market Size, 2001-2012
• Table 3.3: Diagnostic Pharmacogenomic Testing Market Size, 2001-2012
• Table 3.4: Benefits of Pharmacogenomic Diagnostics in Patient Care
• Table 3.5: Genotyping Pharmacogenomic Testing Market Size, 2001-2012
• Table 3.6: Benefits of Pharmacogenomics in Clinical Trials and Drug Development
• Table 3.7: Five Key Action Points for Pharmaceutical Companies
• Table 3.8: Global SNP Identification Tools Market Size, 2004-2012
• Table 3.9: Pharmacogenomic Testing Market Structure
• Table 3.10: P450 Isozymes and Pharmaceuticals
• Table 3.11: List of Companies that Market Pharmacogenomic Tests
• Table 3.12: Key Collaborations in the Pharmacogenomics Industry
• Table 3.13: Prominent Drugs Withdrawn from the Market
• Table 3.14: Key Elements in the Drug Development Process
• Table 3.15: Major Suppliers of PCR-based Assays and PCR-based Technologies
• Table 4.1: Methods for Performing NAT
• Table 4.2: SNP Databases
• Table 4.3: Myriad Genetics Predictive Medicine Sales, 2001-2008
• Table 4.4: DNA-based Predictive Medicine Product Sales for Cancer, 2006-2010
• Table 4.5: Developmental Atherosclerosis Drugs
• Table 4.6: Summary of Assays for HIV Viral Load Testing
• Table 4.7: U.S. Market Share of HIV Testing Kits
• Table 4.8: Global HIV Statistics, 2007
• Table 4.9: List of Approved HIV/AIDS Rapid Test Kits, 2009
• Table 4.10: Monogram Bioscience, Inc. Products for HIV Testing
• Table 4.11: CCR-5 Receptor Agonists in Development, 2009
• Table 4.12: Asthma Therapeutic Drug Pipeline
• Table 4.13: Psychiatric Case Studies, Organized Pharmacokinetically
• Table 4.14: Antidepressant Drugs Decreased Clearance with DME CYP2D6
• Table 4.15: Antidepressant Drugs with No Effect Clearance with DME CYP2D6
• Table 5.1: Examples of Gene-Drug Pharmacogenomic Relationships
• Table 5.2: Estimated Cost and Time for Typing of the BRCA1 Gene by Direct Sequencing vs. SNP Array
• Table 5.3: Average Cost of Resistance Testing, 2007
• Table 6.1: U.S. Prescription Drug Expenditures, 2003-2015
• Table 6.2: U.S. Pharmaceutical Market, 1996-2009
• Table 6.3: Top Ten Global Pharmaceutical Companies by Global Sales, 2007
• Table 6.4: Pharmaceutical Companies Ranked by Total R&D Expenditures, 2007
• Table 6.5: Leading Therapy Classes for R&D, 2008
• Table 6.6: Leading Therapy Classes by Global Pharmaceutical Sales (Audited Market), 2007
• Table 6.7: Number of NME Approvals and Mean Approval Times, 1984-2008
• Table 6.8: Global Market for Tools and Consumables Used in Drug Discovery and Development, 1999-2010
• Table 6.9: Leading Therapeutic Classes by U.S. Sales, 2006 and 2007
• Table 6.10: Top Ten Therapeutic Classes by U.S. Dispensed Prescriptions, 2006 and 2007
• Table 6.11: Top Ten Brand Drugs by U.S. Retail, 2007
• Table 7.1: Select Companies Developing Cancer Diagnostics Available as Analyte Specific Reagents (ASRS)
• Table 7.2: Emerging Fields in Biological Science with the Potential to Impact Personalized Medicine

RNA Interference Markets

1. Overview

• 1.1 Objectives
• 1.2 Scope
• 1.3 Methodology
• 1.4 Executive Summary

2. RNA Interference (RNAi)

• 2.1 Introduction
• 2.2 Overview of RNA Interference
  • 2.2.1 Classes of Endogenous Small RNAs: siRNA, rasiRNA and miRNA
  • 2.2.2 Mechanism of RNAi In Vivo
• 2.3 Glossary
• 2.4 What Areas of Research Does RNAi Impact?
  • 2.4.1 RNAi Technology in Life Sciences Research, Drug Discovery and Development
  • 2.4.2 RNAi Technology in Agriculture

3. Technology Trends in RNAi Space

• 3.1 Overview
• 3.2 End-User Segmentation
• 3.3 Technologies for Inducing RNAi
  • 3.3.1 Methods for Detecting Gene Silencing
  • 3.3.2 Comparison of Strategies for Target Validation
  • 3.3.3 Libraries of siRNAs/shRNAs to Knock Down Genes En Masse
• 3.4 miRNA-Based RNAi: The Leading Edge of RNAi Space
  • 3.4.1 Biological Function of miRNAs
  • 3.4.2 Role of miRNAs in Disease
  • 3.4.3 miRNA-based Diagnostics
  • 3.4.4 miRNA-based Therapeutics
• 3.5 Market Shifts in RNAi Space: Where Is It Headed?
  • 3.5.1 Intellectual Property and Patent Issues
  • 3.5.2 Patents Covering the Molecular Characteristics of the RNAi Agent
  • 3.5.3 Funding in RNAi Space: Grants, Venture Capital and IPOs
  • 3.5.4 Partnerships, Alliances, Mergers and Acquisitions
• 3.6 SWOT Analysis of Technologies and Vendors in RNAi Space

4. RNAi Market Analysis

• 4.1 Overview
• 4.2 Market Data Collection and Respondent Pool
  • 4.2.1 Respondent Pool Characteristics
• 4.3 RNAi Technologies / Products in Research Applications
• 4.4 RNAi Technologies/Products: Market Shares (Quantitative)
• 4.5 Quantitative Metrics of RNAi Usage: Market Opportunity and Growth
  • 4.5.1 Growth of Various Segments in RNAi Space
  • 4.5.2 Product Formats and Representation in RNAi Marketplace
• 4.6 RNAi Marketplace: Challenges, Unmet Needs and Drivers
  • 4.6.1 Unmet Needs in RNAi Space
  • 4.6.2 RNAi Market: Qualitative Growth Drivers

5. The RNAi Landscape

• 5.1 Overview
• 5.2 Market Segmentation of RNAi and Segment Characteristics
• 5.3 Quantitative Market Opportunities in RNAi Space
  • 5.3.1 Opportunities in miRNA Space
  • 5.3.2 Opportunities in siRNA/shRNA Space
• 5.4 RNAi Product Offerings and Associated Business Models
• 5.5 Challenges for RNAi Therapeutic Development

6. RNAi-Based Therapeutics: The Emerging Industry Landscape

• 6.1 Factors Contributing to the Success of RNAi Therapeutics
• 6.2 Advantages and Disadvantages of siRNA-based Drugs
• 6.3 Opportunities and Challenges with RNAi-based Therapeutics
• 6.4 The Gene Therapy Precedent
• 6.5 The Antisense Precedent
• 6.6 Interferon Response
• 6.7 Delivery of RNAi-based Therapeutics
• 6.8 Off-Target Effects
• 6.9 Overwhelming the Endogenous RNAi System-Affecting the microRNA Pathway
• 6.10 RNAi-based Therapeutics
  • 6.10.1 Cancer
  • 6.10.2 Cardiac Disease
  • 6.10.3 Immunologic Disease
  • 6.10.4 Infectious Disease
  • 6.10.5 Inflammation
  • 6.10.6 Lifestyle Therapeutics
  • 6.10.7 Metabolic Disease
  • 6.10.8 Neurologic Disease
  • 6.10.9 Ophthalmic Disease
  • 6.10.10 Renal Disease
  • 6.10.11 Respiratory Disease

7. Company Profiles-U.S.

• 7.1 Alfacell Corporation
• 7.2 Allele Biotechnology and Pharmaceuticals, Inc.
• 7.3 Alnylam Pharmaceuticals
• 7.4 Ambion
• 7.5 Asuragen, Inc.
• 7.6 Avalon Pharmaceuticals, Inc.
• 7.7 B-Bridge International, Inc.
• 7.8 Bio-Rad Laboratories
• 7.9 Calando Pharmaceuticals, Inc.
• 7.10 Cepheid
• 7.11 Cequent
• 7.12 Clontech Laboratories, Inc.
• 7.13 CombiMatrix Corporation
• 7.14 Cyntellect, Inc.
• 7.15 CytRx Corp.
• 7.16 Dharmacon
• 7.17 Dicerna
• 7.18 Galenea Corporation
• 7.19 GeneCopoeia, Inc.
• 7.20 GeneThera, Inc.
• 7.21 Genlantis
• 7.22 GenoSensor
• 7.23 GRL, Inc.
• 7.24 IDT
• 7.25 Imgenex Corporation
• 7.26 Ingenuity Systems
• 7.27 Intradigm Corporation
• 7.28 Invitrogen
• 7.29 InvivoGen
• 7.30 Isis Pharmaceuticals, LLC
• 7.31 LC Sciences
• 7.32 Lentigen Corporation
• 7.33 MDRNA
• 7.34 Merck & Co., Inc.
• 7.35 Mirus Bio Corporation (Acquired by Roche)
• 7.36 Monsanto
• 7.37 Nastech Pharmaceutical Company, Inc.
• 7.38 New England BioLabs
• 7.39 Nucleonics, Inc.
• 7.40 Open Biosystems, Inc.
• 7.41 OPKO Health, Inc.
• 7.42 OriGene
• 7.43 Panomics, Inc.
• 7.44 PhaseRx
• 7.45 Promega Corp.
• 7.46 Quark Pharmaceuticals, Inc.
• 7.47 RXi Pharmaceuticals Corporation
• 7.48 Senetek PLC
• 7.49 Sigma-Aldrich
• 7.50 Sirna Therapeutics
• 7.51 Sirnaomics, Inc.
• 7.52 SomaGenics, Inc.
• 7.53 System Biosciences
• 7.54 Tacere Therapeutics
• 7.55 Targeted Genetics Corporation
• 7.56 Third Wave Technologies
• 7.57 Traversa

8. Company Profiles-Europe

• 8.1 Actigenics SA
• 8.2 Amaxa
• 8.3 AstraZeneca PLC
• 8.4 Cenix Bioscience GmbH
• 8.5 deVGen N.V.
• 8.6 DNAVision
• 8.7 Exiqon
• 8.8 Genovis
• 8.9 genOway
• 8.10 imaGenes GmbH
• 8.11 MWG Biotech AG
• 8.12 OZ Biosciences
• 8.13 Prosensa Holding
• 8.14 QIAGEN
• 8.15 RNAx GmbH (Germany)
• 8.16 Roche
• 8.17 Rosetta Genomics, Ltd.
• 8.18 Santaris Pharma A/S
• 8.19 Silence Therapeutics PLC
• 8.20 TaconicArtemis GmbH
• 8.21 TRANSAT

9. Company Profiles-Asia-Pacific

• 9.1 alphaGEN Co., Ltd.
• 9.2 Benitec, Ltd.
• 9.3 Bioneer
• 9.4 CytoPathfinder, Inc.
• 9.5 Genesis Research & Development Corp.
• 9.6 GeneDesign, Inc.
• 9.7 GNI Pharmaceutical Corporation
• 9.8 Koken Co., Ltd.
• 9.9 NanoCarrier Co., Ltd.
• 9.10 Oncolys Biopharma, Inc.
• 9.11 RealGene Bio-Technologies, Inc.
• 9.12 Samchully Pharmaceuticals
• 9.13 Samyang Corp.
• 9.14 Shanghai Biochip
• 9.15 Shanghai GenePharma Co.
• 9.16 Shanghai Genomics, Inc.
• 9.17 Transgene Biotek, Ltd.

10. Company Profiles-Rest of the World

• 10.1 Benitec, Ltd.
• 10.2 Tekmira

INDEX OF TABLES

• Table 2.1: Advantages/Disadvantages of siRNAs and shRNAs as Inducers of RNAi in Mammalian Cells
• Table 2.2: Prevalence of siRNA-mediated RNAi in Disease Models, as Reported in Scientific Literature
• Table 2.3: RNAi-based Therapeutics in Clinical Trials
• Table 2.4: Suppliers of Enabling Technologies and Tools in RNAi Space
• Table 2.5: Suppliers of siRNA/shRNA Products (by Product/Service Class)
• Table 3.1: Currently-Utilized Technologies for Inducing RNAi-Mediated Knockdown
• Table 3.2: Comparison of mRNA Detection Technologies
• Table 3.3: Strategies for Target Validation by Pharma/Biotech: RNAi and Others
• Table 3.4: Comparison of Formats for Library-Based Gene Knockdown
• Table 3.5: Characteristics of Various Publicly-Available Mouse and Human RNAi Libraries
• Table 3.6: Disease-Related miRNAs
• Table 3.7: Publicly-Available Computational Programs for Identifying miRNA Sequences/Targets
• Table 3.8: Seminal Patents in RNAi
• Table 3.9: Venture Capital Raised by Selected Companies in the RNAi Space
• Table 3.10: List of Public Biotech Companies in RNAi Space
• Table 3.11: SWOT Analysis of siRNA Oligonucleotides
• Table 3.12: Transfection Reagents (Lipid-Mediated Delivery)
• Table 3.13: shRNA Plasmid Constructs
• Table 3.14: shRNA Pooled Libraries or Arrayed Collections (Retroviral/Lentiviral Delivery)
• Table 5.1: RNAi Market Segmentation and Research Settings
• Table 5.2: Segment 1: Basic Life Science Research Utilizing RNAi Tools and Technologies
• Table 5.3: Segment 2: RNAi for Drug Discovery and Development
• Table 5.4: Segment 3: RNAi Research for Development of RNAi Therapeutics
• Table 5.5: Segment 4: RNAi Fee-for-Service Business
• Table 5.6: Grants Awarded and Research Spending in miRNA Space, 2005 to 2008
• Table 5.7: RNAi Opportunity and Market Size: Quantitative Model, 2006 to 2009
• Table 5.8: Challenges for RNAi Therapeutic Development
• Table 5.9: Technology Platforms used in RNAi Research
• Table 6.1 : Similarities Between Antisense Oligonucleotides and siRNAs
• Table 6.2: Disadvantages of siRNA Versus Antisense Oligonucleotides
• Table 6.3: Delivery Vectors for siRNA and Hairpin-Encoding DNA for In Vivo Experiments.
• Table 6.4: Delivery Systems for siRNA and Hairpin-Encoding DNA for In Vivo Experiments.
• Table 6.5: Delivery Systems for RNAi-based Therapeutics
• Table 6.6: Diseases for RNAi Therapeutics
• Table 6.7: RNAi-Based Therapeutics Pipeline-Broken Out by Disease/Therapeutic Area
• Table 6.8: RNAi-Based Therapeutics Pipeline-Broken Out by Stage of Development
• Table 6.9: Most Common Types of Cancer
• Table 6.10: RNAi Therapeutics for Cancer in Phase I
• Table 6.11: RNAi Therapeutics for Cancer in IND
• Table 6.12: RNAi Therapeutics for Cardiac Disease in IND
• Table 6.13: RNAi Therapeutics for Cardiac Disease in Pre-clinical/Research
• Table 6.14: RNAi Therapeutics for Immunologic Disease in Pre-clinical / Research
• Table 6.15: RNAi Therapeutics for Infectious Disease in Phase II
• Table 6.16: RNAi Therapeutics for Infectious Disease in Phase I
• Table 6.17: RNAi Therapeutics for Infectious Disease in IND
• Table 6.18: RNAi Therapeutics for Infectious Disease in Pre-clinical/Research
• Table 6.19: RNAi Therapeutics for Inflammatory Disease in Pre-clinical/Research
• Table 6.20: RNAi Therapeutics for Life Style Therapies in IND
• Table 6.21: RNAi Therapeutics for Metabolic Disease in Pre-clinical/Research
• Table 6.22: RNAi Therapeutics for Neurologic Disease in Pre-clinical/Research
• Table 6.23: RNAi Therapeutics for Ophthalmic Disease in Phase III
• Table 6.24: RNAi Therapeutics for Ophthalmic Disease in Phase II
• Table 6.25: RNAi Therapeutics for Ophthalmic Disease in Phase I
• Table 6.26: RNAi Therapeutics for Ophthalmic Disease in Pre-clinical/Research
• Table 6.27: RNAi Therapeutics for Renal Disease in Phase I
• Table 6.28: RNAi Therapeutics for Respiratory Disease in Pre-clinical/Research
• Table 7.1: Nucleonics Products and Programs Ongoing/Pipeline
• Table 7.2: Quark' s Product Pipeline
• Table 8.1: Santaris' Product Pipeline
• Table 8.2: Silence Therapeutics' Product Pipeline

INDEX OF FIGURES

• Figure 2.1: The miRNA Processing Pathway
• Figure 2.2: Growth of Scientific Publications Addressing miRNAs, 2001 to 2008
• Figure 2.3: Mechanisms of Small RNA-induced Gene Regulation
• Figure 2.4: Types of RNAi Compounds
• Figure 2.5: Breakdown of Scientific Publications Related to RNAi by Geographic Region, 2007 to 2008
• Figure 3.1: End-User Segmentation of RNAi Space
• Figure 3.2: RNAi Patents Filed Globally, by Geographical Origin
• Figure 3.3: Selected Deals in RNAi Space
• Figure 4.1: Geographical Breakdown of RNAi End-User Survey Respondents
• Figure 4.2: Affiliation of RNAi End-User Survey Respondents
• Figure 4.3: Utilization of RNAi Technologies/Products by Respondent Pool
• Figure 4.4: RNAi Utilization Period: Breakdown of Respondent Pool
• Figure 4.5: Research Applications Using RNAi Technologies/Products
• Figure 4.6: Types of RNAi Technologies Currently Utilized
• Figure 4.7: RNAi Technologies Most Commonly Utilized Currently by End-Users
• Figure 4.8: Types of RNAi Technologies: Expected Use in Six to 18 Months
• Figure 4.9: Evolution of Market Shares of RNAi-Inducing Technologies
• Figure 4.10: Number of Experiments Involving RNAi Conducted per Week
• Figure 4.11: Range of Research Dollars Spent Monthly on RNAi Research
• Figure 4.12: RNAi Experiment Throughput Correlated with Type of RNAi Technology Used
• Figure 4.13: Current RNAi Market Share by Segments
• Figure 4.14: Growth/Decline Rate of RNAi Marketplace Segments (Six to 18 Months)
• Figure 4.15: Product Formats Utilization for RNAi Research (Current and Six to 18 Months)
• Figure 4.16: Companies Offering Product Formats for Currently-Used RNAi Products
• Figure 4.17: RNAi Product Offerings/Formats Use (Projections-Six to 18 Months)
• Figure 4.18: Percentage Change of RNAi Product Offerings/Formats (Six to 18 Months)
• Figure 4.19: Key Challenges Faced by End-Users in RNAi Space
• Figure 4.20: Unmet Needs in RNAi Space Ranked by Importance to End-Users
• Figure 5.1: Growth and Evolution of miRNA Space
• Figure 5.2: Elements of RNAi Value Chain
• Figure 5.3: Growth and Evolution of RNAi (siRNA/shRNA) Space
• Figure 5.4: Market Revenues Based on Components of siRNA Experimental Paradigm

Related Reports